AU2002301374A9 - Stable biocidal composition - Google Patents

Description

-1- Regulation 3.2

AUSTRALIA

PATENTS ACT, 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT

ORIGINAL

Name of Applicant: Actual Inventor: Address for service NUFARM LIMITED Allen Paul SORENSEN and Mark Colin VICKERS in Australia: A J PARK, Level 11, 60 Marcus Clarke Street, Canberra ACT 2601 Invention Title: STABLE BIOCIDAL COMPOSITIONS Details of Associated Provisional Application: NZ336139/336213/336814 4 June 1999/10 June 1999/19 July 1999 The following statement is a full description of this invention, including the best method of performing it known to me/us -1- STABLE BIOCIDAL COMPOSITIONS The present invention relates to pesticidal compositions, their preparation and their use.

More particularly the present invention relates to multiple active ingredient liquid formulations of a kind where for stability purposes different environments are required for at least two of the active ingredients. For instance, when in an aqueous phase pH requirements for stability differ significantly, eg; a low pH is required for levamisole and a neutral pH is required for abamectin, a macrocyclic lactone (ML) (see Table 2 hereafter). Also of the common anthelmintics, levamisole salts are usually much more soluble than morantel salts in aqueous systems, M.L anthelmintics are generally more soluble in organic systems than aqueous systems and benzimidazoles are sparingly soluble.

A particular (but not only) area of interest in stable formulation are those formulations of biocides useful in controlling helminths including nematodes, cestodes, trematodes, and/or ectoparasites. In this respect the mode of administration including oral, injectable or pour-on (transdermal) routes of such a formulation (whether after aqueous dilution or not) is not critical to the invention.

It is known that simultaneous administration of levamisole and mebendazole [E M Bennet, C Behm, and C Bryant, Int J Parasitology, 1978, 8,463-466] enhances the anthelmintic activity of benzimidazoles. New Zealand Patent 208288 discloses compositions which contain levamisole and at least one substituted benzimidazole carbamate.

It is also known, based on mathematical modelling that combining 3 or more actives that act to kill a pest in different ways reduces the risk of parasite developing resistance to each of the individual actives if used separately and on their own.

It is also known that it is desirable for ease of use that these actives are combined together in one stable formulation so that administration is by one single administration of an oral, injectable, parenteral or pour-on formulation. It is also desirable that this combined formulation is sufficiently stable so that it can be stored and the formulation used or reused at a later date without degradation of the actives or significant physical changes to the formulations.

Anderson et al in "Mixtures of Anthelmintics: A Strategy Against Resistance" Australian Veterinary Journal, Vol 65, No.2, February 1988, Pages 62-64 suggested that where multiple resistance to broad spectrum nematocides had arisen, treatment with mixtures of nematocides provided effective control of the nematode infections sufficient for use in resistance preventative programs. Hence the need now, much later than 1988, for combined active formulations.

Ancare New Zealand Limited formulated a double active anthelmintic of levamisole and niclosamide in paraffin oil (LEVITAPET m to target both tapeworm and roundworm found any water contamination rendered the product too viscous to use.

They tried PEG 6000 wax encasement of niclosamide to protect it from water to no avail. They even tried a detergent based mixture of niclosamide and levamisole but whilst stable it was not safe nor easy to use as a oral drench.

Ancare found that combining benzimidazole drenches with levamisole drenches results in an unstable product due to the different pH values needed to maintain the stability of the individual products. Often, on standing for an hour or two the drenches separate out with the levamisole on top and the benzimidazole left as a sludge on the bottom. It these are not thoroughly mixed again before use the animal may be under or overdosed. A possible consequence of underdosing with the benzimidazole is the build up of a parasite resistant to the benzimidazole.

Merck NZ 183847 discloses avermectin anthelmintic compounds for parenteral administration where they may be carried by a vegetable oil such as peanut oil, cotton seed oil and the like.

Sankyo NZ 199817 refers to oral formulations of two or more anthelmintics where one is a macrolide (or ML) anthelmintic and another may be, for example, a benzimidazole (eg; albendazole), a salicylamide (eg; niclosamide) or an isoquinoline compound (eg; praziquantel). Such formulations are not exemplified by any storage stable formulation although reference is made to formulation as an aqueous solution, as a solution in another suitable non-toxic solvent or as a suspension or dispersion incorporating a suspension aid and a wetting agent (eg; bentonite) or other constituents.

Doramectin is available from Pfizer as DECTOMAX m as a parenteral formulation of sesame oil and ethyl oleate.

Ashmont NZ 280085/280134 discloses injectable ML anthelmintic formulations (eg; abamectin or ivermectin) where a alcohol (such as benzyl alcohol long since used as a preservative in injectable formulations) acts as a co-solvent with a vegetable oil vehicle (eg; soyabean oil, sesame oil or corn oil). The optional inclusion of ethyl oleate is also disclosed.

Ashmont further discloses (w/w a formulation as follows; ML anthelmintic active 0.5 to 5% w/w benzyl alcohol 1 to 30% w/w vegetable oil to 100% w/w -3ethyl oleate zero or 5 to 30% w/w Despite combinations above being developed no stable ML anthelmintic and levamisole combination has been marketed. Previous attempts at such a combination resulted in unstable formulation see our own Examples 1 6 hereafter.

The present invention is directed to compositions having at least two actives preferably each usable as an anthelmintic active (albeit with a different spectrum of efficacy with respect to nematodes, trematodes, flukes, etc.) and preferably involving other therapeutic agents.

In another aspect the present invention relates to a benzimidazole containing composition (eg; for pour-on use) where the benzimidazole is solubilised in an organic acid containing phase (eg; lactic acid).

As used herein the term "anthelmintic" and derivatives thereof shall encompass, where the context allows any one or more of a nematocidal, trematocidal and cestocidal active compounds. Where the context so allows "pesticidal" and derivatives thereof shall include any such anthelmintic and any ectoparasitocidal compound. Where the context allows "ectoparasitocidal" shall include compounds effective against any one or more of ticks, lice, flies, et al.

As used herein the term "stable" means at least 3 months (preferably at least 18 months) chemical stability (eg; within plus or minus 10% of its stated composition) of the active ingredients when stored at 25 0 C or below and at ambient humidity and of reasonable physical stability such that the composition is substantially homogeneous (despite any option particulate inclusion(s)) and/or can readily be agitated to such condition.

As used herein the term "particle", "particles" and "particulate" means true particles (ie; parts of solids) as well as liposomes or the equivalent optionally which may be or carry an active ingredient. Preferably said particles are almost exclusively less than 100.pt (microns). Ideally the smaller the better (eg; preferably substantially all less than 50p, more preferably less than 3 0p, still more preferably than 20. and even more preferably less than 10 pt).

As used herein the term "solubility" refers to the ability of a compound to be dissolved in a specific phase.

As used herein "lipophilic" means a greater tendency to an organic, oil or the like phase as opposed to the other phase (preferably aqueous).

As referred to herein the term "pourable" or "flowable" in respect of a fluid or liquid covers viscosities ranging from a free flowing liquid to a gel or paste consistency -4that is able to be expelled by syringe, drench or paste gun. The term "pourable" is irrespective of whether it is to be used as a pour on or otherwise.

In a first aspect the invention consists in a pesticidal composition comprising or including at least one active ingredient that is lipophilic in character, (ii) at least one organic liquid carrier which carries at least most of the lipophilic active ingredient(s), thereby defining an organic liquid phase, (iii) levamisole, and (iv) at least water which carries at least most of said levamisole thereby defining an aqueous phase, wherein said aqueous phase has a pH of less than 7, and wherein there is present in said aqueous phase an emulsifying agent or agents, and wherein said phases exist in, or can be shaken or agitated into, the form of an emulsion with said particulate content, if any, at least substantially present in the aqueous phase.

Preferably said pesticidal composition (or indeed any biocidal composition) disclosed herein is a veterinary composition.

Preferably the lipophilic active ingredient is chosen from the class of macro cyclic lactones (hereafter Preferably there is present in said aqueous phase a particulate content.

Ideally said aqueous phase has a pH of less than 6 (more preferably less than and most preferably 4 or below).

Preferably said aqueous phase includes a buffering system to buffer the pH to preferably a pH suitable for the levamisole.

Preferably said buffering system is a citric acid/citrate salt system.

Preferably said at least one organic liquid carrier is an oil vegetable or mineral, or mixtures thereof).

Preferably said organic liquid phase includes a co-solvent.

Preferably said co-solvent is benzyl alcohol.

Preferably said aqueous phase includes a particulate content of either an active agent or an inert substance.

Preferably the particulate active agent is a biocide.

Optionally the composition includes in one or other, or both, of the partitioned phases one or more of the group comprising minerals and vitamins.

In another aspect the invention is an anthelmintic composition having about 0.08% ivermectin, about 3% levamisole, and about 2% albendazole where different liquid carrier phases substantially partition the ivermectin from the levamisole, and where the albendazole is particulate and is at least in part in an aqueous phase with the levamisole, such aqueous phase being buffered to a pH appropriate for the levamisole and its stability.

All percentages are expressed as w/v except where otherwise stated.

In another aspect the present invention consists in a storage stable pourable pesticidal composition having an organic first liquid phase and another ("second") liquid phase, said first phase including at least one active ingredient (and optionally a co-solvent for said active ingredient) and said second phase including a second active ingredient wherein the presence of an emulsifying agent and/or anti-flocculants ensures stability of the two phases with the first phase with its first active ingredient as an emulsion within said second phase with its second active ingredient.

Preferably said second phase is an organic acid and/or aqueous phase.

Preferably said second phase comprises or includes an organic acid such as lactic acid.

Preferably said first phase comprises an oil and/or emollient ester.

Preferably said active ingredients in each of said phases or which might be present as an additional active in both or either phase comprises any of the examples hereinafter provided.

In another aspect the invention consists in a stable mix of two or more immiscible liquids or liquid phases held together by an emulsifier or emulsifiers where one phase is an organic water immiscible phase and another phase is an aqueous or organic phase (eg; water or organic acid(s) such as lactic acid).

In another aspect the present invention consists in a benzimidazole composition comprising an organic acid (such as lactic acid) and the benzimidazole dissolved therein.

In yet a further aspect the present invention consists in a topical or pour-on benzimidazole composition where the benzimidazole is solubilised in an organic acid (such as lactic acid).

In yet a further aspect the present invention consists in a benzimidazole containing composition where at least one phase is that of an organic acid (such as lactic acid) which solubilises at least one benzimidazole active ingredient.

In another aspect the invention consists in a ready to use pesticidal veterinary liquid composition of at least a first active in a first liquid phase and at least a second active in a second liquid phase, the phases forming a stable emulsion.

Optionally a third active may be present in one or other or both of said phases.

Optionally such third active may be suspended in at least one phase.

Preferably each of said first and second actives are dissolved (at least in part) in their respective phases.

In another aspect the present invention consists in a preferably storage stable pourable composition comprising or including up to 25% w/v of at least one pesticide (hereafter "first active(s)") soluble in an organic phase, 1 to 60% w/v of an organic phase [such as a oil (vegetable or mineral) and/or emollient esters] (hereafter "first liquid phase") in which said first active(s) is (are) at least substantially soluble, 0 5% w/v of a cosolvent for said first active(s), 1 to 15% w/v of an emulsifying agent, 0 to 20% w/v of at least one further pesticidal active (hereafter "second active(s)") not substantially soluble in said first phase, and, means providing a second liquid phase, said composition having at least most of said first active(s) in a first phase and said first phase being emulsified in the second phase which includes said second active(s).

In another aspect the present invention consists in a preferably storage stable composition (whether as a concentrate for aqueous dilution or otherwise) comprising or including up to 25% w/v of at least one pesticide (hereafter "first active(s)") chosen from the class of at least partly oil or emollient ester soluble actives, 1 to 60% w/v of at least one water immiscible organic phase [such as a oil (vegetable or mineral) and/or emollient esters] in which said first active(s) is (are) at least substantially soluble, 0 5% w/v of a cosolvent for said first active(s), 1 to 15% w/v of an emulsifying agent, 0 to 20% w/v of at least one further pesticidal active (hereafter "second active(s)") not substantially soluble in said organic phase which is dissolved in said water and/or (ii) suspended in said water, and, water, said composition having an organic phase with at least most of said first active(s), said organic phase being emulsified in an aqueous phase of said water and said second active(s).

Preferably is one embodiment said first and second active are anthelmintics.

Preferably said organic phase at least includes an oil.

Preferably additional active ingredients are included in said composition whether in said organic phase or said aqueous phase or a mixture of them both.

In one preferred form of the present invention an additional active ingredient may be included in such a way that the composition is a suspo-emulsion.

In another aspect the present invention consists in a storage stable pesticidal composition having an organic phase and an aqueous phase, said organic phase being of an oil and/or emollient ester which includes at least one active ingredient (and optionally a co-solvent for said active ingredient) and an aqueous phase including a second active ingredient which is substantially insoluble in said organic phase wherein the presence of an emulsifying agent and/or anti-flocculants ensures stability of the two phases with the organic phase as an emulsion within said aqueous phase.

Preferably said composition includes still further actives which as particles, liposomes or as liquid globules are suspended in one or other or both of said phases.

For instance preferably said first active may be a broad spectrum anthelmintic such as an ML anthelmintic (eg; abamectin) and said second active is a water soluble active also capable of killing nematodes such as levamisole. An additional active or additional actives may include one or more of suitable actives dissolvable or suspendible or emulsifiable in one or other of the phases having, for example, an additional anthelmintic, or an active with an ectoparasitocidal effect or a flukicidal effect.

Equally this may contain two or more actives that have activity against trematodes such as Flukes or Cestodes, or Ectoparasites.

In another aspect the present invention consists in a pourable pesticidal composition comprising or including at least one active ingredient chosen from the class of macro cyclic lactones (hereafter at least orie active ingredient chosen from the tetramisole/levamisole class, at least one organic liquid carrier (preferably at least one oil and, optionally, at least one organic co-solvent) to provide a first liquid phase, and means providing a second liquid phase, and, optionally, an emulsifying agent or agents, wherein said ML active ingredient(s) is(are) at least primarily in the first phase in solution, and wherein said tetramisole/levamisole class active ingredient(s) is(are) at least primarily in solution in the second phase, and wherein said phases exist in, or can be shaken or agitated into, the form of an emulsion.

In another aspect the present invention consists in a pesticidal composition (whether as a concentrate for aqueous dilution or otherwise) comprising or including at least one active ingredient chosen from the class of macro cyclic lactones (hereafter at least one active ingredient chosen from the tetramisole/levamisole class, at least one organic liquid carrier (preferably at least one oil and, optionally, at least one organic co-solvent), and water, and, optionally, an emulsifying agent or agents, wherein said ML active ingredient(s) is(are) at least primarily in the organic liquid carrier(s) in solution (hereafter referred to as "the organic phase"), and wherein said tetramisole/levamisole class active ingredient(s) is(are) at least primarily in solution in the water (hereafter referred to as "the aqueous phase"), and wherein said organic phase and said aqueous phase exist in, or can be shaken into, the form of an emulsion.

Optionally a co-solvent is present. Preferably such co-solvent is selected from the class of alcohols having multiple carbons (preferably 4 or more) (eg; benzyl alcohol), diols and glycol ethers.

Preferably a third active ingredient is included in the composition.

In one form preferably said third ingredient (if an anthelmintic) is other than an ML anthelmintic and other than an anthelmintic chosen from the tetramisole/levamisole class.

Preferably said third anthelmintic agent is selected from the group including benzimidazoles and probenzimidazoles (eg; albendazole, oxfendazole, triclabendazole), praziquantel, salicylamides (eg; closantel), organophosphates, (napthalophos), clorsulon, nitroxynil, morantel, pyrantel, et al. see Table 2 Spectrum of Activity.

-9- Preferably said third anthelmintic active ingredient is suspended at least primarily in the aqueous phase.

Preferably said aqueous phase includes at least one suspension agent for said third anthelmintic active ingredient.

In still other aspects the present invention consists in a (preferably storage stable) pourable composition comprising or including at least one anthelmintic active (hereafter "first anthelmintic active(s)"), at least one liquid to provide a first phase in which said first anthelmintic active(s) is (are) at least substantially soluble, an emulsifying agent, at least one liquid to provide a second phase, and at least one further anthelmintic active (hereafter "second anthelmintic active(s)") not substantially soluble in said first phase, said composition having a first phase with at least most of said first anthelmintic active(s) and a second phase of at least most of said second anthelmintic active(s).

In still other aspects the present invention consists in a (preferably storage stable) composition (whether as a concentrate for aqueous dilution or otherwise) comprising or including at least one anthelmintic (hereafter "first anthelmintic active(s)") chosen from the class of at least partly oil soluble anthelmintic actives, at least one oil (optionally also with an organic co-solvent) in which said first anthelmintic active(s) is (are) at least substantially soluble, an emulsifying agent, water, and at least one further anthelmintic active (hereafter "second anthelmintic active(s)") not substantially soluble in said oil(s) which is dissolved in said water and/or (ii) suspended in said water, said composition having an organic phase of said oil(s) with at least most of said first anthelmintic active(s) and an aqueous phase of said water and at least most of said second anthelmintic active(s).

Preferably said oil is a vegetable oil or a mineral oil.

Preferably said composition includes a third active.

Preferably said third active is a therapeutic agent such as an antimicrobial and/or still further anthelmintic active (eg; flukicide) and/or an ectoparasitocide (hereinafter "third active(s)").

Preferably said third active(s) is primarily disposed within said aqueous phase although in other forms of the present invention it may be partitioned between the organic and aqueous phases or largely in the organic phase.

Preferably said second anthelmintic active(s) is dispersed substantially homogeneously as a suspension in the water.

Preferably said composition includes any one or more of the following: a co-solvent which is to form part of said aqueous phase, eg; as maybe preferable if the first anthelmintic active(s) is only partially soluble in the vegetable oil(s), mineral(s), vitamin(s), antimicrobial(s), anthelmintic(s), antifreeze(s), thickening agent(s), anti-focculant(s), pH stabiliser(s).

Preferably said vegetable oil(s) is selected from the group including soyabean oil, sesame seed oil, corn oil, sunflower oil, peanut oil and safflower oil.

Preferably said emulsifying agent is Tween 80 and/or Teric 380.

Preferably said second anthelmintic active is selected from the group consisting of levamisole or tetramisole (if a water phase soluble anthelmintic) or a water phase suspendible or dispersible anthelmintic such as a suitable benzimidazole typified by, for example, albendazole or oxfendazole. Alternatively said optional third active is a dispersed benzimidazole.

Preferably said cosolvent is selected from the group including high chain alcohols (such as benzyl alcohol), diols, glycol ethers, and esters (eg; PMP).

Preferably said antimicrobial is selected from the group including benzoic acid, potassium sorbate and parabens.

Preferably said minerals are selected from the group including mineral salts or chelates, eg; selenium, copper, cobalt, iodine and zinc.

Preferably said vitamins are selected from the group including vitamins A, D, E, B and C.

Preferably said antifreeze or freezes is or are selected from the group consisting of propylene glycol and glycerine.

-11- Preferably said thickening agent are selected from the group of cellulose gum, xanthan gum, carbapol and algeinates.

Preferably said anti-flocculants are selected from the group consisting of Terasperse 2500 and 4896 (preferably both).

Preferably said pH stabilisers are selected from the group consisting of citric acid, phosphate salts, etc.

Preferably the or a said organic liquid carrier is an oil.

Preferably said oil is a vegetable oil. In other forms it is a mineral oil (eg; medium grade).

Preferably said vegetable oil is selected from a group consisting of or including soyabean oil, corn oil, sesame seed oil, sunflower oil, peanut oil and safflower oil.

In yet a further aspect the present invention is a stable formulation of a first active in an organic ("first") phase, a second active in a second liquid phase, and additional actives in one or other, or both, said phase(s), and wherein said phases provide a stable emulsion, and wherein at least one (and preferably both) of said first and second actives is (are) an anthelmintic active.

Preferably a third active is a suspended active at least primarily in the second phase (eg; an anthelmintic or ectoparasiticide).

Preferably an emulsifying agent assists in the stability of the emulsion.

In yet a further aspect the present invention is a stable formulation of a first active in an organic phase at least primarily of oil(s), a second active in an aqueous phase, and additional actives in one or other, or both, said organic and aqueous phase(s), and wherein said organic and aqueous phases provide a stable emulsion, and wherein at least one (and preferably both) of said first and second actives is (are) an anthelmintic active.

Preferably a third active is a suspended active at least primarily in the aqueous phase (eg; an anthelmintic or ectoparasiticide).

Preferably an emulsifying agent assists in the stability of the emulsion.

In another aspect the invention consists in a storage stable and pourable pesticidal composition comprising or including at least one active ingredient chosen from the class of macro cyclic lactones (hereafter 12- (ii) at least one organic liquid carrier which carries at least most of said ML active ingredient(s), thereby defining an organic liquid phase, (iii) levamisole, and (iv) at least water which carries at least most of said levamisole thereby defining an aqueous phase, wherein said aqueous phase has a pH of less than 7, and wherein there is present in said aqueous phase either or both an emulsifying agent or agents, and a particulate content, and wherein said phases exist in, or can be shaken or agitated into, the form of an emulsion with said particulate content, if any, at least substantially present in the aqueous phase.

In yet another aspect the invention is an anthelmintic oil in water emulsion carrying at least one macro cyclic lactone (ML) in the oil phase and particles of levamisole and an emulsifying agent for the levamisole in the aqueous phase.

In still another aspect the invention is a partitioned biocidal composition comprising in an organic phase a first biocide, and in an aqueous phase at acid pH a second biocide, said first biocide being unstable chemically at said acid pH.

Preferably said composition has particles suspended in at least the aqueous phase.

Preferably said particles are themselves biocidal.

Preferably said particles are of a benzimidazole anthelmintic.

In a further aspect the invention consists in a method of formulating an anthelmintic composition of a kind having at least one anthelmintic (hereafter "first active(s)"), a liquid or liquids to define a first phase in which said first active(s) is (are) at least substantially soluble, (optionally) an emulsifying agent, at least one further anthelmintic active (hereafter "second active(s)") not substantially soluble in said first phase (optionally) anti-flocculant(s), and, a liquid or liquids to define a second phase, said method comprising or including the steps of providing a mix of said first active ingredient and at least the first phase liquid(s), 13providing a mix of said second active ingredient and at least the second phase liquid(s), and (II) by mixing at least the mixes of and forming an emulsion with at least most of said first active in the first phase and at least most of the second active in the second phase.

In a further aspect the invention consists in a method of formulating an anthelmintic composition of a kind having at least one anthelmintic (hereafter "first active(s)") chosen from the class of(at least partly) oil soluble anthelmintic actives, an oil or oils in which said first active(s) is (are) at least substantially soluble, optionally a cosolvent for said first active(s), an emulsifying agent, at least one further anthelmintic active (hereafter "second active(s)") not substantially soluble in said oil(s), optional anti-flocculant(s), and, water, said method comprising or including the steps of providing a mix of said first active ingredient, the oil(s), the optional cosolvent(s) and the emulsifying agent(s), providing a mix of said second active ingredient the water, and the optional anti-flocculant(s), and (II) by mixing at least the mixes of and forming an emulsion with at least most of said first active in the oil(s) and at least most of the second active in the aqueous phase.

In yet a further aspect the invention consists in an anthelmintic composition so made.

In still other aspects the invention is a method of treating mammals for pests which involves (whether with dilution or not) administering or having self administered to such mammals effective amounts of active(s) of compositions of the present invention.

In still a further aspect the invention consists in the use of an anthelmintic composition of any of the kinds previously defined.

In some forms said use is as an oral, a pour-on or as a parenteral composition (preferably with an anthelminticly effective amount of each active).

Preferred formulations of the present invention comprise: 14- Component 1 water insoluble but mostly or completely oil soluble anthelmintic active.

Component 2 An oil (vegetable or mineral) Component 3 an emulsifying agent Component 4 water Component 5A, 5B, etc. Additional active(s) of which at least one is preferably an anthelmintic active. This or these can be either dissolved in the water phase (such as Levamisole) or suspended in the water phase (such as Albendazole) if insoluble, or both (eg; Levamisole and Albendazole).

The water insoluble active is dissolved in the oil, which is emulsified in water.

The oil protects the active against the pH or constituents present in the water phase.

Additional components can be added to this basic formulation.

Addition 1 if component 1 is only partially soluble in the oil phase then a cosolvent may be necessary (eg; an organic co-solvent).

Addition 2 Minerals/Vitamins Addition 3 An antimicrobial.

Addition 4 Antifreezes.

Addition 5 Thickening agents.

Addition 6 Anti-flocculants.

Addition 7 pH stabilisers.

Preferred components and their concentration ranges and examples are set out in Table 1: Table 1 Function Examples WV Component Active Abamectin or ivermectin 0 1 Component Vegetable Oil Soya bean 1 2 Mineral Oil Medium Grade I Component Emulsifying Agent Tween 80 1 3 Teric 380 Component Water To Volume 4 Component Additional anthelmintic 5B, etc. Water soluble Levamisole 0- Water Insoluble Albendazole or oxfendazole 0 Addition 1 Co-Solvent Includes high chain Alcohols (such as 0 Benzyl Alcohol), diols such as PMP (promyristyl propionate), Glycol Ethers and Esters Addition 2 Minerals Mineral salts or chelates 0 Addition 3 Antimicrobials Benzoic Acid, Potassium Sorbate and 0- 1% Parabens, Benzyl Alcohol 15 Table i Function Examples WIV Addition 4 Antifreeze Propylene Glycol, Glycerine 0 Addition 5 Thickening Agents Cellulose Gum, Xanthan Gum, Carbapol 0 -3% and Algeinates Addition 6 Anti-flocculants Terasperse 2500 0 -7% and 4896 Addition 7 pH Stabilisers Citric Acid, 0 Phosphate salts etc. Preferred actives by reference to activity are now tabulated.

Table 2 Spectrum of Activity Compound Nematodes Cestodes Trematode Protozoa Ectoparasites Gastrointesti Lung- Tapewor Fluke Lice Mite Tick File nal Worms Worms ma S S S A. Macrocyclic Lactones 1. Avermectins ivermectin Abarnectin Doramectin Eprinomectin 2. Milbemycin Moxidectin B- a m 1. PrBenzimdazoles Febantel Netobimin 2. Benzimidazoles (thiazoles) Thiabendarcia Cambendazole 3. Benzimidazoles (cerbamnates) Albendazole +(Giardia) Fendendazole +(Giardia) Mebendazole Rycobendazole Oxfendazole Parrbendazole Triciabendazole -16- Compound Nematodes Cestodes Trematode Protozoa Ectoparasites s C. Imidazothiazole Levamisole

D.

Tetrahydropyrimidazole Morantel Pyrantel E. Salleylamldldes Closaritel +(Haemonch us) Oxyclosanide +(Haenionch us) Rafoxamide +(Haemonch us) Niclosamide

F.

Benzoenedlsuplhonamid e Clorsulon G. Nitraphenolic Compounds Nitroxyinil +(Hiaemonch us)

H.

Pyrazinolsoqulnoline Praziquantel 1. Organa phosphates Napthalophos TrIchiorphon Propetamphos Diazinon Cumaphos J. Synthetic Pyrethroids 17- Compound Nematodes Cestodes Trematode Protozoa Ectoparasites s Cypermethrin Alphamethrin Fiumethrn K. Insect Growth Regulators Diflubenzuron Triflumuron Cyromazine L. Amitraz M. Cyhalothrin N. GABA Inhibitor Fipronil A storage stable veterinary composition of at least one macrocyclic lactone levamisole, and at least one benizimidazole wherein the weight relativity of the ML: levamisoleBZ is substantially 0.04:1.5:1, and wherein different liquid carrier phases substantially partition the ivermeetin from the levamisole, and wherein the albendazole is particulate and is at least in part in an aqueous phase with the levamisole, such aqueous phase being buffered to a pH appropriate for the levamisole and its stability, and wherein the ivermectin is substantially in an organic phase.

Preferred forms of the present invention will hereafter be described by reference to examples and the accompanying drawings in which Figure 1 is a plot from the cattle trial NCOO1 hereafter referred to of Avermectin B 1 a blood levels (ng/mL) against time (hours) for the different modes of administration, Figure 2 is a plot of Levamisole blood levels (pg/ml) against time (hours) for the different modes of administration in cattle, Figure 3 is a plot of Oxfendazole blood levels (pg/ml) against time (hours) for the different modes of administration in cattle, Figure 4 is a plot of Fenbendazole blood levels (pg/ml) against time (hours) for the different modes of administration in cattle, -18- Figure 5 is a plot of Avermectin B 1 a blood level (ng/mL) against time (hours) for the oral combination against a commercial oral formulation in sheep, Figure 6 is a plot of Levamisole blood level (ug/ml) against time (hours) for the oral combination against a commercial oral formulation in sheep, Figure 7 is a plot of Albendazole blood levels (pg/ml) against time (hours) for the oral combination against a commercial oral formulation in sheep, Figures 8 to 10 are stability graphs for each of Abamectin, Levamisole and Albendazole against Time respectively for formulation LB98/92, Figure 11 is a plot of Levamisole content against Time for formulation LB98/92, Figure 12 is a plot of pH against Time for formulation LB98/92, Figure 13 shows stability results and graphs for formulation LB99/01 of Table 7, Figure 14 shows stability results and graphs for formulation LB99/02 of Table 8, Figure 15 shows stability results and graphs for formulation LB99/03 of Table 9, Figure 16 stability graphs of pH changes with time for formulations LB99/54A, LB99/54B, LB99/54C and LB99/54D of Table Figure 17 shows (for a 50°C accelerated stability trial) the change of pH of formulations/drenches of Tables 12 and 13 with time, Figure 18 shows (for a 50 0 C accelerated stability trial) the change of viscosity (cp) of formulations/drenches of Tables 12 and 13 with time, Figure 19 shows (for a 50 0 C accelerated stability trial) the change of mean droplet/particle size of formulations/drenches of Tables 12 and 13 with time.

Figure 20 shows (for a 50 0 C accelerated stability trial) the change of moisture content of formulations/drenches of Tables 12 and 13 with time, Figure 21 shows (for a 50 0 C accelerated stability trial) the change of levamisole content of formulations/drenches of Tables 12 and 13 with time, Figure 22 shows (for a 50 0 C accelerated stability trial) the change of praziquantel content of formulations/drenches of Tables 12 and 13 with time, Figure 23 shows (for a 50 0 C accelerated stability trial) the change of albendazole content of formulations/drenches of Tables 12 and 13 with time, Figure 24 shows (for a 50 0 C accelerated stability trial) the change of ivermectin content of formulations/drenches of Tables 12 and 13 with time, Figure 25 shows (for a 50 0 C accelerated stability trial) the change of abamectin content of formulation/drenches of Tables 12 and 13 with time, Figure 26 shows (for a 50 0 C accelerated stability trial) the change of benzyl alcohol content of formulations/drenches of Tables 12 and 13 with time, -19- Figure 27 shows (for a 50 0 C accelerated stability trial) the change of selenium content of formulations/drenches of Tables 12 and 13 with time, Figure 28 shows (for a 50 0 C accelerated stability trial) the change of cobalt content of formulations/drenches of Tables 12 and 13 with time, Figure 29 shows the positive effect against clumping/aggregation from the presence of particles of Levamisole hydrochloride, the unclumped dish to the right being that (LB99/96C of Table 14) with Levamisole, the others (LB99/96A and LB99/96B of Table 14) having no such presence and clumping, Figure 30 shows the results of freeze/thaw trials (mLs separation 200mL samples being cycled between minus 4°C and ambient for 4 days) for formulations/drenches of Table 15, and Figure 31 shows a photograph of phase separation(A) after freeze thawing compared with a stable homogeneous formulation(B) of the invention.

In the following examples all percentages are weight to volume. These examples show various formulations directed to a resistance strategy which nevertheless are stable and may have additional therapeutic and/or active inclusions.

EXAMPLE 1 Combination Abamectin/Levamisole Drench Abamectin 0.20 w/v Tween 80 8.00 w/v Benzyl Alcohol 3.00 w/v Propylene Glycol 20.00 w/v Na 2

HPO

4 1.03 w/v Citric Acid 0.29 w/v Levamisole HCL 8.00 w/v Sodium Selenate 0.24 w/v Water To Volume w/v This was formulated as follows at ambient temperature.

Mix 1 Dissolved Abamectin in Benzyl Alcohol, mixed in Tween and Propylene Glycol.

Mix 2 Dissolved Levamisole, Na 2 HPO,, Citric acid and Sodium Selenate in water.

Combined mix 1 and 2.

This resultant formulation was physically stable but considered too thin.

To correct this the following Examples 2 4 were thickened with Carbopol or gums.

EXAMPLE 2 Combination Abamectin/Levamisole Drench Abamectin 0.20 w/v Tween 80 8.00 w/v Benzyl Alcohol 3.00 w/v Propylene Glycol 20.00 w/v Na 2

HPO

4 1.03 w/v Citric Acid 0.29 w/v Levamisole HCL 8.00 w/v Sodium Selenate 0.24 w/v Cellulose Guni CMC 0.50 w/v Water To Volume w/v This was formulated as follows; Mix I Dissolved Abamectin in Benzyl Alcohol then add Tween.

Mix 2 Dissolved Levamisole, NaHPO,, Citric acid and Sodium Selenate in water.

Mix 3 Dispersed thickener in Propylene glycol.

Combined Mix 2 and 3 then added Mix 1.

EXAMPLE 3 Combination Abamectin/Levamisole Drench Abamectin Tween 80 Benzyl Alcohol Propylene Glycol NazHP0 4 Citric Acid Levamisole HCL Sodium Selenate Carbopol 934 Water 0.20 w/v 8.00 w/v 3.00 w/v 20.00 w/v 1.03 w/v 0.29 w/v 8.00 w/v 0.24 w/v 0.50 w/v To Volume w/v EXAMPLE 4 Combination Abamectin/Levamisole Drench Abamectin 0.20 w/v Tween 80 8.00 w/v Benzyl Alcohol 3.00 w/v Propylene Glycol 20.00 w/v NaHPO 4 1.03 w/v -21- Citric Acid Levamisole HCL Sodium Selenate Xanthan Gum Water 0.29 w/v 8.00 w/v 0.24 w/v 0.20% w/v To Volume w/v The low pH of these formulations 2, 3 and 4 (pH<4) was identified as unsuitable for long the long-term stability of Abamectin. These completely aqueous formulation approaches were then stopped and it was decided to use a vegetable oil to attempt to encapsulate the Abamectin and possibly protect if from the low pH of the water phase.

An additional active, albendazole, a benzimidazole anthelmintic, was added to the formulation.

EXAMPLE Combination Abamectin/Albendazole/Levamisole Drench Abamectin Albendazole Benzyl Alcohol Teric 215 Teric 216 Propylene Glycol Na 2

HPO

4 Citric Acid Levamisole HCL Sodium Selenate Cobalt EDTA Soyabean Oil Xanthan gum Water 0.10 w/v 2.50 w/v 3.00 w/v 10.0 w/v 10.0 w/v 3.00 w/v 1.05% w/v 1.21 w/v 3.75 w/v 0.12 w/v 0.36 w/v 3.00 w/v 0.32 w/v To Volume w/v This was formulated as follows: Mix 1 Dissolve Abamectin in Benzyl Alcohol. Mix in Terics.

Mix 2 Dissolve Levamisole, Cobalt-ETDA, Citric acid, NaHPO, and Sodium Selenate in water.

Mix 3 Disperse Xanthan gum in Propylene glycol then add 5% of water to form gel.

Combine Mix 1 and 2. Added Albendazole. Then added Mix 1.

-22- This formulation after 2 months accelerated stability assays shows that the Abamectin was degrading. The physical stability of this formulation was also poor with Albendazole flocculating out and with the oil phase showing evidence of curdling.

EXAMPLE 6 Combination Abamectin/Albendazole/Levamisole Drench Abamectin 0.10 w/v Albendazole 1.90% w/v Benzyl Alcohol 3.00 w/v Teric 215 10.0 w/v Teric 216 10.0 w/v Propylene Glycol 3.00 w/v Na 2

HPO

4 1.05 w/v Citric Acid 1.21 w/v Levamisole HCL 3.75 w/v Sodium Selenate 0.12 w/v Cobalt EDTA 0.36 w/v Soyabean Oil 3.00 w/v Xanthan gum 0.32 w/v Water To Volume w/v This formulation like that of Example 6 after 2 month accelerated stability assays also showed that Abamectin was degrading. The physical stability of this formulation was also poor with Albendazole flocculating out and with the oil phase showing evidence of curdling.

To prevent such flocculation Terasperse 4896 and Terasperse 2500 were then trialed.

These theoretically coat the Albendazole and improve the solubility in water.

Teric 380, a more appropriate emulsifying agent for stable vegetable oil emulsions.

The percentage of the oil phase was increased to 10% to increase the partition between the oil/water phase possibly improve Abamectin stability.

EXAMPLE 7 Combination Abamectin/Albendazole/Levamisole Drench Abamectin 0.10 w/v Albendazole 1.90 w/v Benzyl Alcohol 3.00 w/v Terasperse 4896 1.00 w/v Terasperse 2500 2.00 w/v Teric 380 Propylene Glycol Levamisole HCI Sodium Selenate Cobalt EDTA Soyabean Oil Xanthan gum Water 5.00 w/v 3.00 w/v 4.00 w/v 0.12% w/v 1.50 w/v 10.00% w/v 0.20 w/v To Volume w/v This was formulated as follows: Mix 1 Dissolved Abamectin in Benzyl Alcohol. Mix into soyabean oil. Mix in Teric 380.

Mix 2 Added Albendazole and Terasperses to water. Added Levamisole, Cobalt- ETDA. Citric acid and Sodium Selenate.

Mix 3 Dispersed Xanthan gum in Propylene glycol then added 5% of water to form gel.

Combined Mix 1, 2 and 3.

This formulation gave no flocculation but the oil phase readily separated out.

The oil/water phase required further stabilisation. A series of water/oil/emulsifier blends were prepared to optimise this aspect of the formulation. Tween 80 was also trialed as a possible alternative emulsifier to Teric 380. All formulations were stored at ambient.

EXAMPLE 8 Oil/Water Blends Tween 80 10.0 w/v Soyabean Oil 10.0 w/v Water To Volume w/v This was prepared as a simple mixture but the emulsion broke after 4 hours.

EXAMPLE 9 Oil/Water Blends Teric 380 5.0 w/v Soyabean Oil 10.0 w/v Water 85.0 w/v This straight blend broke after 2 days.

-24- EXAMPLE Oil/Water Blends Tween 80 10.0 w/v Soyabean Oil 50.0 w/v Water 40.0 w/v This straight blend emulsion broke after 4 days.

Teric 38 Soyabe Water EXAMPLE 11 Oil/Water Blends 0 5.0 w/v an Oil 50.0 w/v 45.0 w/v This straight blend emulsion broke after 25 days.

As a result we concluded that Teric 380 was the better emulsifier, and the higher concentration of oil emulsion was the most stable option. Therefore we decided to trial with oil at from 35 to 60% w/v.

EXAMPLE 12 Soyabean Oil Abamectin Albendazole Benzyl Alcohol Terasperse 4896 Terasperse 2500 Teric 380 Propylene Glycol Levamisole HCI Sodium Selenate Cobalt EDTA Soyabean Oil Xanthan gum Water 0.10 w/v 1.90 w/v 3.00 w/v 1.00 w/v 2.00 w/v 5.00 w/v 3.00 w/v 4.00 w/v 0.12 w/v 1.50 w/v 40.00 w/v 0.30 w/v To Volume w/v This was formulated as follows at ambient temperature.

Mix 1 Dissolved Abamectin in Benzyl Alcohol. Mix into Soyabean oil. Mix in Teric 380.

Mix 2 Added albendazole and Terasperses to water. Added levamisole, Cobalt- ETDA, Citric acid and Sodium Selenate.

Mix 3 Dispersed Xanthan gum in Propylene glycol then added 5% of water to form gel. Combined Mix 1, 2 and 3.

With this formulation we found no flocculation occurred or separation of the oil was observed. This batch has remained stable after being recycling between 4 0 C, ambient and for 6 months.

Although formulation of Example 12 was showing indications of suitability another formulation option was tested. Xanthan Gum was replaced with Alginate as a alternative thickener.

EXAMPLE 13 Combination Abamectin/Albendazole/Levamisole Drench with alginates Abamectin 0.10 w/v Albendazole 1.90 w/v Benzyl Alcohol 3.00 w/v Terasperse 4896 1.00 w/v Terasperse 2500 2.00 w/v Teric 380 5.00 w/v Propylene Glycol 3.00 w/v Levamisole HCL 4.00 w/v Sodium Selenate 0.12 w/v Cobalt EDTA 1.50 w/v Soyabean Oil 10.00 w/v Alginate (Kelcolid) 0.20 w/v Water To Volume w/v Formulating Order: Mix 1 Dissolved Abamectin in Benzyl Alcohol. Mix into soyabean oil. Mix in Teric 380.

Mix 2 Added Albendazole and Terasperses to water. Added Levamisole, Cobalt- ETDA, Citric acid and Sodium Selenate.

Mix 3 Dispersed Alginate in Propylene glycol then added 5% of water to form gel.

Combined Mix 1, 2 and 3.

-26- Findings: Product appeared stable but a rapid viscosity drop with time was observed. This was followed by eventual slight separation of the water phase in long term stability samples.

EXAMPLE 14 (Batch No. LB99/01) Increasing Benzimidazole (Albendazole) Loading Abamectin 0.10 w/v Albendazole 2.38 wlv Benzyl Alcohol 3.00 w/v Terasperse 4896 1.00 w/v Terasperse 2500 2.00 w/v Teric 380 5.00 w/v Propylene Glycol 3.00 w/v Levamisole HCL 3.75 w/v Soyabean Oil 40.00 w/v Xanthan gum 0.30 w/v Water To Volume w/v Formulating Order: Mix 1 Dissolved Abamectin in Benzyl Alcohol. Mix into soyabean oil. Mix in Teric 380.

Mix 2 Added Albendazole and Terasperses to water. Added Levamisole and Citric Acid.

Mix 3 Dispersed Xanthan gum in Propylene glycol then added 5% of water to form gel.

Combined Mix 1, 2 and 3.

Findings: Product stable under an accelerated stability programme.

The robustness of this formulation concept was examined by substituting Albendazole with Oxfendazole and by increasing active loading.

27 EXAMPLE 15 (Batch No. LB99/03) Substituting Albendazole with Oxfendazole Abamectin 0.10 w/v Oxfendazole 2.26 w/v Benzyl Alcohol 3.00 w/v Terasperse 4896 1.00 w/v Terasperse 2500 2.00 w/v Teric 380 5.00 w/v Propylene Glycol 3.00 w/v Levamisole HCL 3.75 w/v Soyabean Oil 40.00 w/v Xanthan gum 0.30 w/v Water To Volume w/v Formulated similarly to Example 14.

Findings: Product stable under an accelerated stability programme.

EXAMPLE 16 Increasing Albendazole Loading Abamectin 0.10 w/v Albendazole 5.00 w/v Benzyl Alcohol 3.00 w/v Terasperse 4896 2.00 w/v Terasperse 2500 4.00 w/v Teric 380 5.00 w/v Propylene Glycol 3.00 w/v Levamisole HCL 3.75 w/v Soyabean Oil 35.00 w/v Xanthan gum 0.30 w/v Water To Volume w/v Prepared similarly to Example 14.

Findings: Product stable under an accelerated stability programme.

-28- EXAMPLE 17 Benzimidazole Active in Lactic Acid Carnola Oil 40.00 w/v Teric 380 5.00 w/v Abamectin 0.10% w/v Promyristyl Propionate 3.00 w/v Oxfendazole 4.00 w/v Levamisole HC1 3.75% w/v Lactic Acid To volume Formulated Order: Mix 1 Dissolve Abamectin in warmed emollient Ester (Promyristyl Propionate) then mix into Oil. Mix in Teric 380.

Mix 2 To Lactic acid dissolve Oxfendazole and Levamisole (slight heat required).

Mix 3 Combine mixes 1 and 2 with high shear agitation Findings: These soluble forms of benzimidazoles are likely to have advantage (more easily dermally absorbed) as pour-on formulations. May include a thickener.

EXAMPLE 18 Benzimidazole Active in Lactic Acid Carnola Oil 40.00 w/v Teric 380 5.00 w/v Abamectin 0.10% w/v Promyristyl Propionate 3.00 w/v Triclabendazole 0.50% w/v Oxfendazole 4.00% w/v Levamisole HC1 3.75% w/v Lactic Acid To Volume Formulated Order: Mix 1 Dissolve Abamectin in warmed emollient Ester (Promyristyl Propionate) then mix into Oil. Mix in Teric 380.

Mix 2 To Lactic acid dissolve Oxfendazole or Levamisole and Triclabendazole (slight heat required).

Mix 3 Combine mixes 1 and 2 with high shear agitation.

-29- Findings: As above, likely to have application as a pour-on formulation. May include a thickener.

STABILITY

Stability testing with formulations such as Example 7 over 19 months shows a desirability for buffering and a buffering system (citric acid/NaOH) was added.

Laboratory Batch abbreviated to LB and is used synonymously with Batch Number Table 3 LB98/92 Abamectin 0.10%, Albendazole 1.9% and Levamisole 4.0% Triple Active Drench. Stability Conditions 4°C, Ambient and Formulation Material IB98/92 Soybean Oil 40.00% w/v Ethoxylated Caster Oil 5.00% w/v Abamectin @90% 0.11% w/v Benzyl Alcohol 3.00% w/v Albendazole 100% 1.90% w/v Terasperse 4896 1.00% w/v Terasperse 2500 2.00% w/v Cobalt EDTA 1.57% w/v Sodium Selenate 0.12% w/v Levamisole HCI 100% 4.00% w/v Propylene Glycol 3.00% w/v Xanthan Gum 0.30% w/v Citric Acid 0.10% w/v Water to volume As required (to 100%) Summary: See Table 4 (4A, 4B and 4C) for stability results at 4'C, Ambient and 30 0

C.

See Figures 8 to 10 for stability graphs for Abamectin, Levamisole and Albendazole respectively.

See Figures 11 and 12 for graphs with a comparison of pH (Figure 12) and Levamisole content (Figure 11).

Chemical stability appears satisfactory up until 13 month whereafter the pH drifts upwards and Levamisole contents drops. This pH drift/levamisole drop is believed related. Hence pH stabilisation is believed desirable.

TABLE 4 Sample ID: LB98-92 Storage conditions: 4*C, Ambient and Table 4A Stability Summary. 4 Ambient Humidity Initial Results Age/Months at 4'C Criteria 1 2 3 6 9 13 19 Appearance Homogeneous Conforms Conforms Conforms Conforms Conforms Conforms Conforms pink suspension.

Specific Gravity 0.9970 20"C 0.9970 0.9970 0.9970 0.9970 0.9970 0.9970 0.9970 Ph 3.85 3.85 3.95 3.85 3.85 3.80 4.00 4.35 Viscosity 483cps 20"C 413cps 406cps 386cps 366cps 352cps 374cps 334cps (Spindle 2 12rpm) Abamectin (aim 0.10%) 0.100%w/v 0.099% 0.100% 0.100% 0.098% 0.103% 0.097% 0.094% Albendazole (aim 1.88%w/v 1.86% 1.77% 1.84% 1.90% 1.92% 1.90% 1.92% Levamisole (aim 4.13%w/v 4.13% 4.09% 4.08% 4.03% 3.94% 3.98% 3.81% Table 4B LB 98/92 Stability Summary. Ambient Temperature and Humidity Initial Results _Age/Months at Ambient Criteria 1 2 3 6- 9 13 19 Appearance Homogeneous Conforms Conforms Conforms Conforms Conforms Conforms Conforms pink suspension.

Specific Gravity 0.9970 20-C 0.9970 0.9970 0.9970 0.9970 0.9970 0.9970 0.9970 Ph 3.85 3.85 3.90 3.95 3.95 3.90 3.80 4.45 Viscosity 483cps 20'C 330cps 307cps 284cps 276cps 252cps 267cps 334cps (Spindle 2 12rpm) Abamectin (aim 0.10%) 0.100%w/v 0.101% 0.101% 0.101% 0.101% 0.103% 0.099% 0.093% Albendazole (aim 1.88%w/v 1.88% 1.86% 1.90% 1.87% 1.89% 1.90% 1.93% Levamisole (aim 4.13%w/v 4.13% 4.14% 4.09% 4.03% 4.16% 3.92% 3.48% Table 4C LB98/92 Stability Summary. 30'C and Ambient Humidity: Initial Results _____Age/Months at 30"C Criteria 1 2 3 6 9 13 19 Appearance Homogeneous Conforms Conforms Conformns Conforms Conforms Conforms Conforms pink suspension. Specific Gravity 0.9970 20-C 0.9970 0.9970 0.9970 0.9970 0.9970 0.9970 0.9970 Ph 3.85 3.83 3.90 3.90 3.85 3.70 3.80 4.65 Viscosity 483cps @20*C 27Scps 254cps 245cps 26lcps 3Olcps 311bps 3l6cps (Spindle 2 12rpm) Abaniectin (aimO0.10%) 0. 100%w/v 0.100% 0.101% 0.101% 0.102% 0.100% 03100%/ 0.092% [Albendazole (aim 1.88%w/v 1.89% 1.65% 1.83% 1.87% 1.84% 1.90% 1.93% 1Levamnisole (aim 4.13%w/v 4.08% 3.97% 4.09% 4.03% 4.10% 3.95% 3,54% -33- VARIATION IN BENZIMIDAZOLE CONTENT Formulations Table LB 99/01 Abamectin 0.10% Albendazole 2.38% Levamisole 3.75% LB 99/02 Abamectin 0.10% Albendazole 5.00% Levamisole 3.75% LB 99/03 Abamectin 0.10% Oxfendazole 2.26% Levamisole 3.75% Stability Conditions Ambient and 30°C for Formulations of Table Table 6 Material LB 99101 LB 99/02 LB 99/03..

Soybean Oil 40.00% 35.00% 40.00% Ethoxylated Caster Oil 5.00% 5.00% 5.00% Abamectin 90% 0.11% 0.11% 0.11% Benzyl Alcohol 3.00% 3.00% 3.00% Albendazole 2.38% 5.00% Terasperse 4896 1.00% 2.00% 1.00% Terasperse 2500 2.00% 4.00% 2.00% Oxfendazole 100% 2.26% Levamisole HCI 100% 3.75% 3.75% 3.75% Propylene Glycol 3.00% 3.00% 3.00% Xanthan Gum 0.30% 0.30% 0.30% Citric Acid 0.10% 0.10% 0.10% Water to volume As Required As Required As Required See Figure 13 and Table 7 for stability results and graphs for LB 99/01.

See Figure 14 and Table 8 for stability results and graphs for LB 99/02.

See Figure 15 and Table 9 for stability results and graphs for LB 99/03.

Table 7 LB99/O1 Stability Summary. Sheep Drench containing Abamectin, Albendazole and Levamisole. Ambient and 30'C Temperature. Ambient Humidity Product LB99/01 Age Initial Ttlmth T=1 nth T=6nitbs T=6mths Th9mths, T=9mths Thl5mths Storage @,Ambient @30-C @Ambient @30-C @Ambient @30-C @Ambient Conditions perne Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous White White White White White White White White 'White Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Specific Gravity 0.973 20C 0.973 20tC 0,973 20C 0.973 a 20C 0,973 20-C 0.973 20-C 0.973 20C 0.973 20-C 0.973 pH 3.70 3.60 3.65 3.30 3.30 3.18 3.00 3.09 2.96__ Viscosity 2,4l0cps 2,278cps 2,265 2,34Ocps 2,2O2cps 2,24Ocps 2,l92cps 2,22lcps 2,206cps Ahamectin 0.097% 0.098% 0.099% 0.096% 0.095% 1 0.099% 0.097% 0.095% 0.094% Albendazole 2,35% 2.33% 2.34% 2.30% 2.29% 2.26% 2.20% 2.17% 2.26% Levamisole 3,76% 3.74% 3,77% 3.83% 3.77% 3.74% 3.70% 3.73% 3.74% Table 8 LB99/02 Stability Summary. Cattle Drench containing Abamectin, Albendazole and Levamisole. Ambient and 30'C Temperature.

Ambient Humidity Product LB99102 Age Initial__ T=lmth 7=1lmth T=6mnths T=6mths T=9mths =-9mths T=I5mths Ismtbs Storage @Ambient @30-C @Amubient @30-C @Ambient @30-C @Ambient Conditions"_______ Appearance Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous White White White White White White White White White Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Specific Gravity 0.983 0.983 0.983 0.983 0.983 0,983 0.983 0,983 0.983 pH 3.5 3.45 3.40 3.20 3.30 3.00 3.00 3.00 2.95 Viscosity 2,39Ocps 2,2l3cps 2,l99cps 2,lO0cps 1,80cps 2,OS0cps 1,9l1Ocps 2,Ol0cps 1,B7Ocps Abamectin 0.096% 0.097% 1 0.101% 0.103% 0.096% 0.096% 1 0.098% 0.095% 0.092% Albendazole 4.99% 4.97% 4.96% 1 4.97% 4.91% 4.87% 4.9 1% 4.82% 4.78% Levamisole 1 3.78% 1 3,77% 3.74% 1 3.71% 3.72% 3.75% 3.69% 3.78% 3.56% Table 9 LB99/03 Stability Summary. Drench containing Abamectin, Oxfendazole and Levamisole. Ambient and 30 0 C temperature.

Ambient Humidity Product LB99/03 Age Initial T=lmth T=imth T-6mths T=6mths T=9mths T--9mths T=15mths Storage Conditions @Ambient @30'C @Ambient @30'C @Ambient @30'C @Ambient Appearance Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous White White White White White White White White White Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Emulsion Specific Gravity 0.980 0.980 0.980 0.980 0.980 0.980 0.980 0.980 0.980 pH 3.90 3.95 3.90 3.15 3.00 2.85 2.8 2.45 2.40 Viscosity 2,518cps 2,532cps 2,730cps 2,420cps 2,320cps 2,400cps 2,390cps 2,230cps 2,160cps Abamectin 0.097% 0.097% 0.097% 0.101% 0.101% 0.098% 0.096% 0.093% 0.093% Albendazole 2.22% 2.23% 2.26% 2.26% 2.26% 2.22% 2.21% 2.25% 2.31% Levamisole 3.75% 3.73% 3.72% 3.80% 3.86% 3.73% 3.69% 3.14% 3.02% LB99/01 has remained stable for 15 months under ambient and 30"C conditions. A pH drop has been noted.

LB99/02 has remained stable for 15 months under ambient and 30°C conditions although the sample at 30°C is showing indications that Levamisole content may be starting to fall.

LB99/03 has remained stable for 9 months under ambient and 30°C conditions but a significant drop in pH and Levamisole is evident at 15 months.

These trials further indicate that pH stabilisation is desirable for long term stability.

-36pH STABILISATION TRIALS: It is evident from the trends previously noted that some form of pH stabilisation is desirable (if not necessary).

A series of accelerated trials was carried out on a Triclabendazole, Abamectin and Levamisole formulation to study the effects of; 1) Chelated Minerals on pH stability.

2) Citrate Acid/Sodium Citrate buffer system on pH stability.

The trial formulations were stored at ambient and 40 0 C and pH tested regularly for 3 months.

Table 10 Formulation Details for pH Stability Trial LB99154A LB991548 B999154C 4.LB99I 154D; M ineralised' Uhmineraled inris Unminerallsedi No Buffer- NBuore e Buffered t Soybean Oil 40.000% 40.000% 40.000% 40.000% Ethoxylated Caster Oil 5.000% 5.000% 5.000% 5.000% Abamectin 90% 0.110% 0.110% 0.110% 0.110% Benzyl Alcohol 0.750% 0.750% 0.750% 0.750% Triclabendazole 100% 2.500% 2.500% 2.500% 2.500% Terasperse 4896 1.000% 1.000% 1.000% 1.000% Terasperse 2500 2.000% 2.000% 2.000% 2.000% Levamisole HCI 100% 3.750% 3.750% 3.750% 3.750% Cobait EDTA 1.570% 1.570% Sodium Selenate 0.120% 0.120% Citric Acid to pH 3.5 to pH 3.5 1.000% 1.000% NaOH to pH 3.5 to pH Propylene Glycol 3.000% 3.000% 3.000% 3.000% Xanthan Gum 0.250% 0.250% 0.250% 0.250% Water to volume As Required As Required As Required As Required 37 Table 11 Results: pH with time for compositions of Table 10. Ambient and 400 C Temperature. Ambient Humidity Age 99/54A 99/54A 99/54B 99/548 99/64C 99/54C 99/M4D 99/54D (Days) Ambient 40 0 C Ambient 40C Ambient 40CC @'Ambie nt o 3.50 3-50 3.50 3.5 3.5 3.50 3.50 3.50 3 1 3.57 3.61 2.90 2.97 3.55 3.55 3.51 3.55 6 3.62 3.65 2.90 2.70 3.55 3.45 3.51 3.45 3.84 3.95 2.87 2.39 3.60 3.61 3.50 3.50 13 4.01 3.71 2.84 2.29 3.62 3.56 3.52 3.51 18 4.06 3.64 2.86 2.27 3.66 3.61 3.51 3.50 21 3.91 3.70 2.80 2.31 3.60 3.60 3.51 3.51 28 4.16 3.90 2.90 2,34 3.60 3.60 3-50 3.62 1 4.25 4.22 2.85 1 2.25 13.60 1 3.55 3.50 3.60 1 4.27 4.23 2.79 1 2.16 13.55 3.60 3.50 3.66 See Figure 16 for stability graph of pH change with time.

Conclusions and Recommendations: Some of the early batches of the present invention have shown a trend of significant pH changes with time. Mineral chelates also appear to affect the direction the pH change occurs, ie; with mineral chelates pH increases and without these pH decreases. In either case this is likely to have detrimentally effects on the stability of Levamisole which isnormally expected around pH 3.0 to 4.0. Therefore some method of pH stabilising is desirable (if not necessary) for longer term stability.

The Citric Acid/Sodium Citrate system which uses Citric acid/sodium hydroxide (INaOH) appears suitable for this purpose in these formulations. Other pH stabilising systems (such as the Phosphate buffer system) have also been considered.

-38- Comparative Accelerated Stability A study to compare the relative stability of a number of the formulations within the invention with standard commercial formulations at very high temperature (50 0 C) was conducted. The commercial formulations used have shelflives of 2 years or more. Six test formulations B, C, D, E and J) and 4 commercial formulations consisting of 3 single active drenches G, H) and 1 triple active drench were placed under identical conditions, including identical high density polyethylene containers and identical closure systems and placed in a 0 C oven at ambient humidity. In the test formulations of the invention used either abamectin or ivermectin triple active formulations, with or without minerals, buffered or unbuffered, and one had the addition of praziquantel These are detailed in Table 12 and 13.

SUMMARY OF DRENCH PRODUCTS PLACED ON ACCELERATED AMBIENT HUMIDITY) STABILITY: Table 12: DRENCH DESCRIPTION A Abamectin Triple, plain, unbuffered, 20% higher active content B Abamectin Triple, plain, buffered C Ivermectin Triple, plain, buffered D Ivermectin Triple, mineralised, buffered E Ivermectin Quad, mineralised, buffered F IVOMEC T sheep drench (Ivermectin) G NILVERMT m drench (Levamisole) H VALBAZENT M drench (Albendazole) I FIRST DRENCH T M (Albendazole, Praziquantel, Levamisole, mineralised) J Abamectin Triple, mineralised, buffered Formulations A, B, C, D, E and J are formulations of the present invention.

39 Table 13: Formulation details for Test Products used in Accelerated Stability (50'C) _E D C JB

A

Material Content 2.00% Albendazole 2.00% Albendazole 2.00% Albendazole 2.00% Albendazole .2.00% Albendazole 2.50% Albendazole 3.00% Levamrisole 3.0.00/ Levamisole 3.00% Levaiisole 3.00% Levamnisale 30%Levamisole 3.75% Levamisole'.

1.50% Praziquantel 0.08% Ivermectin' 0.08% Ivermectin 0.08% Abamnectin 0.08% Abamnectin 0.10% Abamectin 0.08% Ivermectln, Minerals ,Min6rA~s .,Unbuffered Mhvierals Soybean oil 40.000 40.000 40.000 40.000 40.000 40.000 Teric 3800 5.000 5.000 5.000 5.000 5.000 5.000 Ivermectin 90% 0.088 0.088 0.088 N/A N/A N/A Abamectin 90% NIA N/A N/A 0.088 0.088 0.088 Benzyl alcohol 1.500 1.500 1.500 1.500 1.500 1.500 Albendazole 99% 2.020 2.020 2.020 2.020 2.020 2.020 Terasperse 4896 1.000 1.000 1.000 1.000 1.000 11.000 Terasperse 2500 2.000 2.000 2.000 2.000 2.000 2.000 Praziquantel 98.8% 1.518 N/A N/A N/A N/A N/A Water 25.000 25.000 25.000 25.000 25.000 25.000 Levamiscie HCL 99.5% 3.015 3.015 3.015 3.015 3.015 3.015 Pmopylene glycol 3.000 3.000 3.000 3.000 3.000 3.000 Cobalt Chelate 1.260 1.260 N/A 1.260 N/A N/A Sodium Selenate 0.096 0.096 N/A 0.096 N/A N/A Keltrol F 0.200 0.200 0.200 0.200 0.200 0.200 NaOH (To pH 3.75) Citric acid 1.000 1.000 1.000 1.000 1.000 NIA Water to volume 0 See Figure 19 which is a plot of mean droplet/particle size against time.

POINTS TO NOTE REGARDING 4 WEEK ACCELERATED (50 0 C AMBIENT HUMIDITY) STABILITY RESULTS: pH change greatest for the unbuffered drench A, no other significant differences (Figure 17). The change in pH for all products was greatest in the first two weeks (especially after the first week). However, the changes in pH have not impacted on the physical or chemical stability of any of the formulations. The lack of buffering agent in drench A has not affected the stability of this drench relative to the others, at least not in the short term.

Viscosity decrease was greatest in quad drench E, which started out with the highest initial viscosity (Figure 18). Correlates well with the observed particle size increase (Figure 19). The triple formulations of the present invention showed the best stability with respect to viscosity. In the test formulations the particles measured would predominantly be the oil droplets/particles.

Drench F (IVOMECT

M

has a very low viscosity (>100 x less than preferred formulations of the present invention), hence stability related decreases are not expected to be significant No significant trend in moisture content is apparent (Figure 20). The low values for A and B are due to the variability of the measurement technique as seen on the weekly summary graph. The stability of the moisture content and the physical observations of the integrity of the containers (no change from initial) indicates that the packaging and closure system is adequate for the formulation products of the present invention in the short term at high temperature.

Levamisole loss is consistent at around 10% for all of the drench products (Figure 21). Initial loss of active was rapid (from initial to 1 week through to 2 weeks) but then stabilised.

No significant change in Praziquantel levels was observed (Figure 22).

No significant change in Albendazole levels was observed. (Figure 23).

The Albendazole change for Drench H (VALBAZENTM) was calculated from week 2 to week 4, as the initial results appear to be erroneous.

The Ivermectin (Figure 24) and abamectin (Figure 25) appears stable with similar trends between formulations and no obvious loss of active. The 1 week ivermectin result for drench D appears to have been erroneous.

Benzyl alcohol loss (Figure 26) is consistent across all the products. Drench F

(IVOMEC

TM sheep drench) has twice the level of benzyl alcohol than the formulations of the present invention and also twice the water content.

-41 Selenium (Figure 27)and cobalt (Figure 28) levels in the mineralised drenches show no significant changes over the four week period.

CONCLUSION:

After four weeks of storage at 50 0 C, ambient humidity: The formulations of the present invention show physical and chemical stability that is at least as good as products F, G, H and I available on the New Zealand market There is no difference in the physical or chemical stability of the Ivermectin products versus the abamectin products in formulations of the present invention.

PARTICULATE CONTENT: The stability of the formulation when albendazole particles were removed and substituted with Silicon dioxide and titanium dioxide particles was tested in the following formulations. These were used as pour-on formulations in cattle.

A) Pour-on, Injectable and Gel Formulations: Formulations were developed with higher loading of actives, substituting and loading particulate content using silicon dioxide and titanium dioxide. These formulations were developed to be used as pour-ons, injectible or as oral gels.

The following formulations were prepared.

LB99/96A- 0.5% Ivermectin 1% Silicon Dioxide LB99/96B 0.5% Ivermectin 1% Silicon Dioxide 2.0% Titanium Dioxide as a UV screen.

LB99/96C 0.5% Ivermectin 10.0% Levamisole 1% Silicon Dioxide with Titanium Dioxide.

LB99/72A 0.1% Ivermectin, 3.75% Levamisole, 1.88% Praziquantel with 8% Silicon Dioxide.

-42- Table 14 Ivermectin, Ivermectin/Levamisole and Ivermectin/Levamisole/Praziquantel Formulations With Silicon Dioxide and Titanium Dioxide Added Material LB99/96A LB99196B LB99/96C' LB99172 Soybean Oil 40.00% 40.00% 40.00% 15.00% Teric 380 5.00% 5.00% 5.00% 5.00% Ivermectin 100% 0.50% 0.50% 0.50% 0.10% Benzyl Alcohol 5.00% 5.00% 5.00% 1.50% Levamisole HCI 100% 10.00% 3.75% Colloidal Silicon Dioxide 1.00% 1.00% 1.00% 8.00% Praziquantel 1.88% Titanium Dioxide 2.00% 2.00% Propylene Glycol 3.00% 3.00% 3.00% NaOH (to pH 3.5) 0.21% 0.22% 0.39% 0.37% Xanthum Gum 0.50% 0.50% 0.10% Citric Acid 1.00% 1.00% 1.00% 1.00% Water to volume To volume To volume To volume To weight Appearance Off white fluid which White fluid which Homogeneous white Homogeneous white separates on standing separates on standing fluid gel pH 3.5 3.5 3.5 Viscosity 1,600cps 1,800cps 3,100cps >100.000cps Note that Colloidal Silicon Dioxide was added to the formulation as a substitute for the solid component (such as Albendazole, Oxfendazole and Triclabendazole) that might desirably be found in the oral formulations. Titanium Dioxide filled a similar function to such benzimidazole solids insofar as stability is concerned as well as an UV screen.

Observations: The solid component in LB99/96A and LB99/96B rapidly settled after agitation even though both formulations had five times as much Xanthan gum as LB99/96C. LB99/96C's higher viscosity and superior suspension properties is attributed to an interaction of Xanthan gum with the chloride portion of Levamisole Hydrochloride. See Figure 29.

Formulation LB99/96C was also considered suitable for an injectable formulation but ideally would have the silicon dioxide/titanium dioxide substituted with a readily biodegradable/metabolised particle and the levamisole hydrochloride substituted by levamisole phosphate to be less irritant at the injection site.

43 Formulation LB99/72A formed a white thick pourable gel which was considered to have application for example orally in horses, dogs and cats.

B)_WaterTolerance: Test The pour-on formulations listed in Table 14 (LB99/96A, LB99/96B and LB99/96C) were mixed with 10% extra water and any effect observed.

Result No gelling. The additional water and drench phase mixed cleanly and no other reaction observed. This was also confirmed in other formulations including Example 12.

C)QDrenchability: Test Formulations of the present invention (such as LB 99/96A, LB99/96B and LB99/96C of Table 14) were applied though a standard drench gun containing residual water.

Result Again no gelling occurred and the gun operated smoothly. Drenches of the present invention are unlikely to negatively affect the performance of the drench guns.

The presence of oil in the formulation would likely act as a lubricant.

FREEZE/THAW TRIALS: The physical characteristic of drenches of the present invention when repeatedly frozen and then thawed was investigated. A series of Triclabendazole, Abamectin and Levamisole drenches, LB99/52A to LB99/52G (see Table 15) were formulated and was cycled between minus 4'C 4°C) and ambient conditions daily for 4 days.

Their response to these conditions was compared to that of a number of current standard suspension drenches; SYSTAMEXM, VALBAZEN T m and FIRST

DRENCH

T M Table 15 Test Formulations Used in Freeze Thaw Trials Material LB99/52A LB99/52B LB99/52C LB99/52D LB99/52E LB99/52F LB99/52G Soybean Oil 40.00% 40.00% 40.00% 40.00% 40.00% 40.00% 40.00% Teric 380 5.00% 5.00% 5.00% 5.00% 5,00% 5.00% 7.50% Abamectin 100% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% Benzyl Alcohol 0.75% 0.75% 0.75% 0.75% 0.75% 0.75% 0.75% Triclabendazole@100% 2.50% 2.50% 2.50% 2.50% 2.50% 2.50% 2.50% Terasperse 4896 1 00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% Terasperse 2500 0% 1.00% 2.00% 3.00% 4.00% 2.00% 2.00% Levamisole HCI 100% 3.75% 3.75% 3.75% 3.75% 3.75% 3.75% 3.75% -44 Cobalt EDTA 1.57% 1.57% 1.57% 1.57% 1.57% 0% 1.57% Sodium Selenate 0.12% 0.12% 0.12% 0.12% 0.12% 0% 0.12% Propylene Glycol 3.00% 3.00% 3.00% 3.00% 3.00% 3.00% 3.00% Keltrol F 0.3% 0.30% 0.30% 0.30% 0.30% 0.30% 0.30% Citric Acid 0.1% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% Water to volume As Required As Required As Required As Required As Required As Required As Required LB99/52C is considered a "standard" with 1.0% Terasperse 4896, 2.0% Terasperse 2500, 5.0% Teric 380 and minerals.

LB99/52A as per standard but no Terasperse 2500.

LB99/52B as per standard but 1.0% Terasperse 2500.

LB99/52D as per standard but 3.0% Terasperse 2500.

LB99/52E as per standard but 4.0% Terasperse 2500.

LB99/52F as per standard but no minerals.

LB99/52G as per standard but 7.5% Teric 380.

RESULTS Table 15 Formulations 200mL's of each formulation was stored in clear 250mL glass bottles and examined for separation, homogeneity and sediment. These results are also presented in graph form in Figure Terminology in Table 16 Sep I or Separation top- mL's of clear material forming separate above any suspended material or sediment.

Sep I or Separation Bottom- mL's of clear material forming separate below any suspended material.

Hm or Homogeneous no indication of settling or sedimentation.

Table 16 LB99152A LB99/52B LB99/52C LB99/52D LB99/52E LB99/52F LB99/52G Systamex Valbazen First Drench Day 1 Hm Hm Hm Sep t 2mLs Sep I 2mLs Hm Sep I 2mLs Hm Sep 1 25mLs Sep I Day 2 Hm Hm Sep I 1mLs Sep I 5mLs Sep I SmLs Sep I 1mLs Sep L 5mLs Hm Sep I 25mLs Sep 1 Day 3 Sep L 3mLs Sep I 3mLs Sep I 5mLs Sep 1 10mLs Sep s Sep Sep mL s Sep Sep I 20mLs Hm Sep T 30mLs Sep I Day 4 Sep I 5mLs Sep I 4mLs Sep I 12mLs Sep I 20mLs Sep 1 25mLs Sep I 12mLs Sep 1 70mLs Hm Sep t 5mLs Sep 1 See Figure -46 Discussion: The following trends were evident; 1) Increasing the surfactant content (Teric 380 and Terasperse 2500) in a formulation of the present invention decreases it's physical stability under severe freeze thaw conditions.

2) Minerals have no noticeable effect on freeze/thaw properties.

3) Drenches of the present invention differ from standard suspension drenches in the way they separate. Standard drenches separate to form a clear layer on top, while drenches of the invention form a similar layer on the bottom. This may be due to density. Suspended solids are usually heavier than water and may sink, while oil-based emulsions, as in drenches of the present invention, are usually lighter than water and may remain in the top portion. In physically unstable formulations of the present invention there is a top phase of oil, a middle phase of suspended solids, and a bottom water layer phase.

This is illustrated as A in Figure 31. This contrasts with the physically stable formulation (B of Figure 31) which remained homogeneous.

4) A standard formulation of the present invention containing 5.0% Teric 380 and 2.0% Terasperse 2500 appears to separate out less than VALBAZEN m and FIRST DRENCHTh drenches.

5) All suspension drenches readily re-suspended with minimal agitation.

6) All drenches of the present invention readily re-emulsified with minimal agitation.

7) After storage in the freezer all drenches froze solid. The drenches of the present invention melted significantly faster than the traditional suspension drenches. Drenches of the present invention were fluid in less than minutes while the suspension drenches took several hours.

Stability Conclusions The results of the accelerated stability trials at 30'C for up to 19 months and comparative stability at 50'C for 1 month, demonstrate that within the invention there are formulations with multiple actives that are chemically and physically stable 47 including combinations of previously incompatible actives such as the ML's (ivermectin, abamectin) and Levamisole. In addition, the freeze/thaw trials, water tolerance, substitution and loading of actives demonstrate these are versatile and robust formulations suitable for field use. The presence of particulate matter, a suitable buffering system to maintain a stable acid pH, the presence of suitable and appropriate amounts of thickening agents, emulsifiers and oil have also been shown to determine the stability of these formulations. Surprisingly, increasing amounts of emulsifying agents were found to increase the physical instability and phase separation with freeze/thawing. The presence of a particulate material (such as a benzimidazole) and also levamisole hydrochloride was found to contribute positively to physical stability.

Additionally not only were formulations found to be very versatile, capable of holding four actives simultaneously in one stable formulation, but the suspoemulsion's physical characteristics overcome some problems associated with current commercial suspensions. For example, in current benzimidazole suspensions, the particles with time settle and stick to the bottom of containers and are difficult to resuspend. This can affect the concentration and amount of active dosed. In the current invention, the particles settle toward the middle liquid layer not the bottom and so particles are readily available for resuspension.

The oil within the formulation also acts as lubricant in the drench gun. It is common farming practice to leave drench guns to sit with traditional suspensions within them. Over time there is settling out of particles and a drying out of the product including around the plunger. This can result in the particulate material abrading and damaging the drench gun when reused. In the current invention, the oil keeps the drench gun lubricated, making such damage less likely.

Animal Trials Overview The following animal trial data in cattle and sheep demonstrates that when given orally the combination of anthelmintics in the experimental formulations appears equally bio-available based on blood profiles (Trials NC001, NC002), when compared with commercial standard formulations alone, and this is supported by the egg count and worm kill data.

The benefits of combining previously incompatible actives together in one formulation is also demonstrated, with greater control of resistant or dose limiting gastro intestinal worms under experimental and field conditions. This benefit is 48 demonstrated both with the oral formulations in sheep (Trials C052 and C0040) and as a pouron (Trial C012-400) in cattle.

In addition, mathematical models suggest there are long term benefits in the use of combination products with three or more actives from different action families both in extending and preserving the life of currently known anthelmintic or biocidal compounds.

ANIMAL TRIALS Cattle Pilot Study (NC 001) Oral and Pour-on Treatment Thirteen mixed breed weaner beef cattle (90-153 kg) from Northern New South Wales, Australia naturally infected with gastrointestinal roundworms were divided into four treatment groups by weight and nematode faecal egg count (FEC) into three groups of three animals and a fourth group of four animals.

Animals in group 2 were treated with the test combination formulation orally (Batch LB99/03, see example 15) at a dose of lmL per 5 kg bodyweight. Group 3 of four animals had the same product (Batch LB99/03) applied as a pour-on along the midline of the upper back at a dose of 1 mL per 2.5 kg bodyweight. Group 4 received the same dose rate of the three actives as in group 2 given orally using three separate commercial formulations. Group 1 received no treatment (untreated control animals).

Animals were treated at Day 0 of the trial. Faeces for faecal egg count and blood samples for blood levels of active were collected at various times following treatment.

Slaughter was at Day 14 of the trial where the total number of worms were counted in the gastrointestinal tract.

The results are presented below and in the drawings.

49 Table 17 Treatment Groups Group, No. of. Treatment' Route Cone Batch No. Dose' Animals "(Active) 1 3 No Treatment 2 3 Combination Test Oral Formulation (Example 15) Abamectin 22.6g/L LB99/03 Oxfendazole 37.5g/L Levamisole 3 4 Combination Test Pour On Formulation (Example 15) I.0g/L Abamectin 22.6g/L LB99/03 Oxfendazole 37.5g/L Levamisole 4 3 Commercial Formulations Per Label Virbamec (abamectin) Oral 0.8g/L 33245 V2 Systamex (oxfendazole) Oral 90.6g/L 153 Young's Levamisole Oral 37.5g/L 004 (levamisole) 3183

RESULTS

Table 18 Faecal Egg Counts (strongyle eggs/gram) Group Treatment Day Day Day Day Day Day Day Day Day Day 0 -1 2 3 "4 5 6 13 1 Nil 685 439 811 521 380 311 208 249 249 272 (Untreated control) 2 Oral 491 2 0 0 0 0 0 0 0 0 Combination Formulation (Example 3 Pour-on 441 10 0 0 0 0 0 0 0 0 Combination Formulation (Example 4 Oral 701 2 0 0 0 0 0 0 0 0 Commercial Formulations Treatment Day Day 0 Table 19 Total Worm Count Individual Animal Data Group' Treatment Animal. Haemonchus.. Trichostongylus-: Ostertagiai Cooperla. Oesophagostamum No. placet axel, bstertagi Spp. radlatum 1 Untreated 3100 440 1240 340 1900 29 1 Untreated 3101 340 140 3140 2240 6 1 Untreated 3102 220 0 1120 3340 76 2 Oral Comb 3103 0 0 0 0 0 2 Oral Comb 3104 0 0 0 0 0 2 Oral Comb 3105 0 0 0 0 0 3 Pour-on Comb 3106 0 0 0 0 0 3 Pour-on Comb 3107 0 0 0 0 0 3 Pour-on Comb 3108 0 0 0 0 0 3 Pour-on Comb 1079 0 0 0 0 0 4 Oral Comm 3109 0 0 0 0 0 4 Oral Comm 1077 0 0 0 0 0 4 Oral Comm 1078 0 0 0 0 0 In the drawings Figure 1 is a plot of Avermectin B la blood levels (ng/mL) against time (hours) for the different modes of administration, Figure 2 is a plot of Levamisole blood levels (pg/ml) against time (hours) for the different modes of administration, Figure 3 is a plot of Oxfendazole blood levels (j.g/ml) against time (hours) for the different modes of administration, and Figure 4 is a plot of Fenbendazole blood levels (pg/ml) against time (hours) for the different modes of administration.

RESULTS

The trial confirmed that the combination formulation (example 15, Batch LB99/03) was a highly effective anthelmintic in cattle both orally and as a pour-on. This is demonstrated by a complete (100%) reduction in faecal egg count, two days following 51 treatment and a greater than 99.9% reduction of gastrointestinal nematodes compared with untreated controls.

The blood profiles of abamectin, levamisole and oxfendazole with the test product (example 15) given orally were essentially similar to those achieved in animals receiving the three commercial formulations of these actives. The higher blood levels of oxfendazole in the combination product were probably because of the oily nature of the formulation. Such differences have been seen previously between oily and aqueous benzimidazole formulations (Hennessy 1996). The blood profiles in pour-on treated animals shows that levamisole blood levels were similar to those achieved orally, the abamectin were ten times lower than with the commercial oral abamectin formulation and low levels of oxfendazole and fenbendazole (a metabolite) were detected in blood.

Sheep Pilot Study (NC 002) Oral Treatment Nine 17-20 month old merino hoggets from Northern New South Wales, Australia naturally infected with gastrointestinal roundworms were allocated on the basis of parasite faecal egg count (FEC) to 3 treatment groups of 3 animals, each group having a similar mean FEC.

At treatment day (day 0) animals in Group 1 received no treatment (untreated controls), Group 2 received the combination product orally as detailed in example 14 (Batch No. LB99/01) and Group 3 received the same dose of actives using 3 separate commercial formulations (abameetin, levamisole and albendazole) given orally.

Faeces for parasite FEC and blood for blood levels of active were collected at various times following treatment (day Animals were slaughtered at day 14 following treatment, with total numbers of worms counted within the gastrointestinal tract.

The results are presented below and in the drawings.

52 Table 20 Treatment Groups Group No. of Treatment Route Cone Batch No. Dose Animals (Active) i 1 3 No Treatment (controls) 2 3 Abamectin Albendazole Oral 23.8g/L LB99/01 Levamisole 37.5g/L 3 3 Virbamec (abamectin) 0.8g/L 33425 V2 Valbazen (albendazole) Oral 19g/L 7003 Per Label Young's Levamisole 37.5g/L 3183 (levamisole) Results Table 21 Faecal Egg Counts (Strongyle Eggs/gram) Group Treatment Day Day Day Day Day Day Day 0 4 3 4. "13 1 Nil 2205 2093 2543 1198 1930 3078 1351 2 Oral Combination 2213 722 0 0 0 0 0 Formulation (Example 14) 3 Oral Commercial 2475 150 0 0 0 0 0 Formulations Table 22 Total Worm Counts Individual Animal Data Abomasal Nematodes Group Treatment Animal No. Haemonchus Ostertaga Trihostrongylusl contortus circumcincta axel 1 Nil 1 760 720 580 1 Nil 2 80 2220 840 1 Nil 3 180 1520 560 2 Oral Comb 4 0 0 0 2 Oral Comb 5 0 0 0 2 Oral Comb 6 0 0 0 3 Oral Comm 7 0 0 0 3 Oral Comm 8 0 0 0 3 Oral Comm 9 0 0 0 53 Table 23 Total Worm Counts Individual Animal Data Small and Large Intestine Nematodes Group Treatment Animal Cooperia Nermatodlrus. Trichostrongylus Oesophagostomum No Spp. spathiger, colubriformis, columblanum 1 Nil 1 340 1480 8260 144 1 Nil 2 760 1760 6040 137 1 Nil 3 60 1540 4800 134 2 Oral Comb 4 0 0 0 0 2 Oral Comb 5 0 0 0 0 2 Oral Comb 6 0 0 0 0 3 Oral Comm 7 0 0 0 0 3 Oral Comm 8 0 0 0 0 3 Oral Comm 9 0 0 0 0 In the drawings Figure 5 is a plot of Avermectin Bla blood level (ng/mL) against time (hours) for the oral combination against a commercial oral formulation, Figure 6 is a plot of Levamisole blood level (tg/ml) against time (hours) for the oral combination against a commercial oral formulation, and Figure 7 is a plot of Albendazole blood levels (atg/ml) against time (hours) for the oral combination against a commercial oral formulation.

Results The trial confirmed that the combination formulation (example 14, Batch No.

LB99/01) was a highly effective anthelmintic when given orally in sheep. This was demonstrated by a complete (100%) reduction in faecal egg count by day 2 and a greater than 99.9% reduction in all major worm species in the gastrointestinal tract.

The blood profiles of abamectin, levamisole and albendazole with the test product (example 14) were essentially similar to those achieved in animals receiving commercial formulations of the same three actives.

54 CATTLE POUR-ON TRIAL (CO012-400) S Cattle Thirty Friesian and Friesian cross weaner beef cattle (113-189kg) naturally infected with gastrointestinal roundworms were randomly allocated into 5 treatment groups of 6 animals with mean faecal egg counts per group of 100-183 eggs per gram at treatment day.

One group (treatment A) remained as untreated controls, the other 4 treatment groups were treated with a pour-on formulation at Day 0 as described in Table 24 using a syringe held 3-5cm above the animal skin with the products applied along the midline of the back between the shoulder blades (withers) in a line approximately 15cm long.

This area was chosen to prevent calves licking themselves and they were observed after pour-on treatment to ensure that licking of other calves, particularly the pour-on site, did not occur.

In this trial the benzimidazole (albendazole or oxfendazole) which is particulate and exists in the water phase had been substituted with fine particles of silicon dioxide (Si0 2 alone or in combination with titanium dioxide (TiQ See Formulations LB 99/96A, LB 99/96B, LB99/96C illustrated in Table 14). This was to determine if titanium dioxide which is used in sunscreens could significantly protect the ivermectin in the formulation. Ivermectin is degraded by UV light. Additionally the ivermectin content was increased from 0.1% to 0.5% to reduce the volume that needed to be applied to the animal (lmL per 10kg liveweight). This also allowed a comparison with a commercial ivermectin formulation IVOMEC T m pour-on which has a similar concentration of ivermectin.

The animals were slaughtered at day 8 and faeces (for faecal egg count) and the abomasum (stomach) and small and large intestines were collected for total gastrointestinal roundworm count. The results are presented in Tables 25 and 26.

There were insufficient numbers of large intestinal worms to allow comparison.

55 Table 24 Treatment groups and formulation data Treatment Groups Group No. of Treatment Controls or gl/00mL Dose Rate 'Batch No.. Expiry or Animals Conceritration (mLs per kg Manufacture Sbodywelght Date S- W) A 6 Controls B 6 Commercial Ivomec 1mL per 10kg HJ11640 Exp 12-2001 Pour-on (B) Ivermectin C 6 Test Product C ImL per 10kg LB 99/96A Date of Man Ivermectin 0.5% 11199 Silicon Dioxide 1% D 6 Test Product D 1 mL per 10kg LB 99/96B Date of Man Ivermectin 0.5% 11/99 Silicon Dioxide 1% Titanium Dioxide 2% E 6 Test Product E ImL per 10kg LB 99/96C Date of Man Ivermectin 0.5% 11/99 Levamisole hydrochloride Silicon Dioxide 1% Titanium Dioxide 2% Results Only the test pour-on formulation containing both ivermectin and levamisole (formulation LB 99/96C) significantly reduced the faecal egg counts in treated animals.

The egg count in Group E reaching zero (100% reduction) at Day 8 post treatment.

This can be explained by the greater Cooperia worm kill in the small intestine of this treatment group. Cooperia is a highly prolific egg producing worm. Of these pour-ons only the ivermectin and levamisole combination (formulation LB 99/96C) was highly effective in removing adult Cooperia with a 95% or greater reduction in Cooperia worm numbers compared with untreated controls.

Both the commercial ivermectin formulation and the three test ivermectin pour-on formulations (LB 99/96A, LB 99/96B and LB 99/96C) were highly effective against adult stages of the abomasal worm Ostertagia. Titanium dioxide did not provide any significant improvement in worm kill (based on comparison of worm kill between formulation LB 99/96A and LB 99/96B). There was no significant skin or hair changes observed at the pour-on skin site suggesting the formulations were well tolerated and suitable as pour-on formulations. Observations of the formulations at the time of pour- 56 on application were that pour-on formulations LB 99/96A and LB99/96B both appeared physically unstable with rapid separation of the formulation. This was not true of the ivermectin and levamisole formulation (LB 99/96C) which remained homogeneous. See photo Figure 17. This was an unexpected observation. In this trial the addition of levamisole hydrochloride to the test ivermectin pour-ons significantly extended the spectrum of activity of the pour-on to include Cooperia and also appears to contribute to the formulations physical stability.

-57- POUR-ON CATTLE TRIAL (C012-400) Table 25 Liveweight, Dose Rate and FEC Data Faecal Egg Count (eggs per gram) Treatment ID Livewelght Dose Day -7 Day 0 Day 8 (ml) 17-Nov 23-Nov 36860 A. Control 10 167 50 0 14 165 500 400 1850 63 166 0 100 100 64 143 0 0 116 200 200 100 73 154 250 400 750 Means 166 183 475 B. Ivomec Pour-on B 2 136 13.6 100 300 450 Commercial 7 134 13.4 150 150 1200 Formulation 11 189 18.9 250 250 250 Batch HJ11640 70 144 14.4 0 0 0 Exp 12-2001 71 152 15.2 350 550 1250 Dose Rate mLUl Okg 74 150 15 450 250 450 Means 216 250 600 C. Test Pour-on C 8 167 16.7 150 50 0 (Ivm/SIlO,) 67 154 15.4 250 400 Formulation LB 99196A 68 118 11.8 650 300 2600 lmL1Okg 69 157 15.7 150 0 0 72 122 12.2 200 350 600 202 124 12.4 0 0 0 Means 233 183 533 D. Test Pour-on D 3 176 17.6 550 100 450 (lvmfTi02/SiO,) 4 113 11.3 200 0 ormulation LB 99196B 6 144 14.4 350 350 100 Dose Rate lmLO10kg 9 136 13.6 200 400 250 12 149 14.9 50 0 0 148 14.8 250 0 850 Means 266 141 275 E. Test Pour-on 1 138 13.8 50 0 0 vm/Lev/TIO 2 5 152 15.2 500 50 0 Formulation LB 99196C 13 154 15.4 750 200 1ml/10kg 61 '157 15.7 1000 300 0 62 183 18.3 150 0 0 66 145 14.5 150 50 0 Means 433 100 0 Means 1 Control 166 183 475 2 Ivomec Pour-on B 216 250 600 3 Test Pour-on C 233 183 533 4 Test Pour-on D 266 141 276 1i 5 Test Pour-on E 433 100 0 No faecal sample.

-58- POUR-ON CATTLE TRIAL (CO12-400) Table 26 Worm Count Data Abomasum Small Intestine Ostertagia Trichostrongylus axel Cooperia FEC Mature J Immature Mature Immature Mature Immature (Day 8) A. Controls 50 1300 200 50 450 14 1850 2950 350 150 6500 1450 83 100 1300 350 150 1000 150 4 1000 50 3450 600 100 1350 100 2450 300 73 750 5650 300 18100 2250 lean 2258 225 58 5325 792 B. Ivomec P.O.

atch HJ11640 2 450 __3100 350 7 1200 __3600 200 1 250 150 50 3000 100 0 -_1200 100 1r 1250 50 7300 500 '4 450 150 2600 400 Mean 600 58 8.3 0 3466 275 C. Test P.O. IVM Si Batch LB 99/96A____ B 0 50 800 37 50 -_12300 150 68 2600 400 3500 i 69 0 50 2000 72 600 -50 2550 202 0 50 400 Mean 533 100 8.3 0 3592 33 D. Test P.O. IVM+TIO+SIO, atch LB 99/96B 450 100 50 6800 250 S- 2300 3 100 50 50 2500 9 250 -200 50 3800 12 0 200 200 150 4000 850- 750 Mean 275 58 75 41.6 3358 58 E. Test P.O. IVMILEV+TiO,+ SiO, Batch LB 99/96C 1 0 100 0 200 50 350 13 150 50 200 61 0 100 62 0 -_200 6 0 250 50 100 Mean 0 100 16.6 58 133 Efficacy B 0 97.4 96.3 100 35 Arithmetic C 0 95.6 96.3 100 33 96 D 42 47.4 66.6 28 37 93 E 100 95.6 92.6 0 97.5 96.8 Efficacy B 98,3 98.7 0 0 Geometric C 95 98.7 20.7 96.2 D 98,3 89.5 0.1 92 E 97.8 96.6 94.8 93.8 59 SHEEP TRIAL (CO52) An anthelmintic drench trial was conducted on a sheep farm in North Auckland, New Zealand using 67 Romney and Romney cross suffock lambs (18-35kg bodyweight) of mixed sex. The farm had a history of illthrift, scouring and lamb deaths consistent with gastrointestinal roundworm parasitism despite regular 4 weekly oral drenching.

The 67 lambs were randomly allocated by egg count into 4 groups of 10 lambs (Groups A, B, C, D) and 3 groups of 9 lambs (Groups E, F, The 3 groups of 9 lambs F G) were drenched with a commercial formulation from one of the three broad spectrum anthelmintic drench families consisting of albendazole, a member of the benzimidazole or white drenches (Group levamisole, a member of the imidazothiazole tetrahydropyrimidazole or clear drenches (Group F) and Ivermectin, a member of the macrocyclic lactones (Group Of the 4 remaining groups, Group A remained as untreated controls, Group B received the unmineralised test product (formulation 00-27C) containing all 3 actives (albendazole, levamisole, ivermectin), Group C received the same basic formulation but with the addition of selenium as the sodium selenate (formulation 00-27B) and Group D received the same basic formulation but with the addition of both selenium and cobalt with cobalt given as the cobalt chelate (formulation 00-27A) See Table 27.

All animals were weighed and dosed by syringe to the nearest 0.lml with the appropriate product for that group. Six days after oral treatment the animals were slaughtered and faecal samples were collected at slaughter. The liveweight, dose rates and faecal egg count data are presented in Table 28.

TEST

FORMULATIONS FOR SHEEP TRIAL (CO52): Table 27: Theoretical Actual 00-27A 00-27B 00-27C (Adusted 3 Litre Batch 2 Litre Batch 2 Litre Batch for potency) 2.00% Albendazole 2.00% Albendazole 2.00% Albendazole 3.00% Levamisole 3.00% Levamisole 3.00% Levamlsole 0.080% Ivermectin 0.080% Ivermectin 0.080% Ivermectin SeCo Se Plain Soybean Oil 40.000 40.000 1200.00 800.00 800.00 Teric 380 5.000 5.000 150.00 100.00 100.00 Ivermectin @90% 0.080 0.088 2,64 1.76 1.76 Benzyl Alcohol 1.500 1.500 45.00 30.00 30.00 Albendazole 99% 2.000 2.020 60.60 40.40 40.40 Terasperse 4896 1.000 1.000 30.00 20.00 20.00 Terasperse 2500 2.000 2.000 60.00 40.00 40.00 Water 25,000 25.000 750.00 500.00 500.00 Levamisole HCI 3.000 3.015 90.45 60.30 60.30 99.5% Propylene Glycol 3.000 3.000 90.00 60.00 60.00 Cobalt Chelate 1.260 1.260 37.80 Sodium Setenate 0.096 0.096 2.88 1.92 Keltrol F 0.200 0.200 6.00 4.00 4.00 NaOH (to pH 3.75) Citric Acid 1.000 1.000 30.00 20.00 20.00 Water to Volume to 100 mL N/A to 3,000 mL to 2,000 mL to 2,000 mL Results: The egg counts at slaughter in the untreated animals and the less effective anthelmintics were considerably higher than at treatment day (Day The most likely explanation for this is reduced volume and flow of intestinal contents. This is likely the result of reduced food intake and a greater colonic absorption of water because of yarding the previous day (Day 5) increasing the concentration of eggs per gram of faeces. Despite this, a comparison with the egg counts of the untreated control animals -61is valid and gave reductions in egg count of 79% for ivermectin, 63% for albendazole and only 22% for levamisole (based on arithmetic mean).

These egg count reductions suggest resistance to all 3 drench families and are well below reductions typically seen with these drench families in susceptible worm populations. All test combination formulations (00-27A, 00-27B, 00-27C) gave 100% reductions in egg count, with greater than 95% reduction considered to indicate a highly effective anthelmintic treatment.

This trial confirmed the benefits of combining all 3 actives in the test formulations.

This combination resulted in a highly effective anthelmintic drench, despite resistance being present on this farm to each of the 3 anthelmintic drench families when given separately.

Table 28 Trial (C052) Faecal Egg Counts at Treatment Day and Day 6 ""Tag Body- Dose Egg Count Egg Count Tag Body- Dose Egg Count Egg Count weight Rate (Day 0) (epg) (Day 6) weight Rate (Day 0) (Day 6) n (kg) (mL) (kg) (mL) (ep) (epg) A. Untreated E. Albendazole (Abz) Valbazen Batch 51660 Exp Feb 2001 (1 mL per 5kg 1112 25.2 400 14200 526 21.7 4.3 300 2600 1113 21.5 -200 "100 527 20.7 4.1 0 700 1114 27,9 400 12100 528 20.2 4.0 200 1600 1115 28.3 100 3200 529 19.8 4.0 300 6800 1116 20.5 0 0 530 32.3 6.5 600 3100 1117 25.3 200 8000 532 20.6 4.1 100 4900 1118 30.7 0 2900 533 26.6 5.3 0 300 1119 24.6 100 16300 659 21.7 4.3 100 1700 1120 25.4 300 3700 660 24.7 4.9 200 0 1121 20.8 0 4200 Mean 200 2411 (630%) Mean 170 6470 B. Test Formulation Batch No. 00-27C F. Levamisole (Lev) Nilverm Batch 51930 Exp Nov 2004 (Ivm,Lev,Abz, Plain) (1 mL per 5.33kg 7.5mg kg) (1 mL per 4kg 200ug/7,5mg/5.Omg/kg) 1 135 35.5 8.9 400 0 701 19.8 3.7 100 15500 136 15.8 4.0 100 0 702 24-0 4.5 100 1100 137 24.7 6.3 0 703 26.9 5.1 200 4300 139 21.9 5.5 0 0 704 22.4 4.2 0 3700 140 25.5 6.4 0 0 705 21.1 4.0 300 4700 141 29.9 7.5 800 0 31.0 5.8 500 200 142 23.0 5.8 200 0 707 23.2 4.4 200 3700 1 T'3 30,0 7.5 100 0 708 19.0 3.6 400 1400 144 24.0 6.0 600 0 834 24.7 4.7 0 10900 145 27.7 6.9 100 0 Mean 200 5055 (22%) Mean 260 0 62 C. Test Formulation Batch No. 00-27B G. Ivermectin (Ivm) Ivomec Batch Y8289 Exp Nov 2002 (Ivm, Lev, Abz, Se) (1 mL per 4kg 200ug/kg) (1 mL per 4kg 200ug/7.5mg/5.0mg/kg) 176 33.8 8.5 200 0 876 25.5 6.4 100 0 177 23.6 5.9 0 0 877 24. 6.2 300 178 24.9 6.2 300 0 878 29.4 7.4 200 0 179 21.3 5.3 200 0 879 25.0 6.3 0 0 180 18.2 4.6 400 0 880 24.0 6.0 300 600 181 19.6 4.9 600 0 881 32.1 8.0 100 0 182 265 900 0 882 19.8 5.0 800 100 183 24.2 6.0 0 0 883 29.9 5.7 0 11000 309 29,3 7.3 100 0 1008 28.4 7.1 400 0 310 29.5 7.4 100 0 Mean 244 1377 (79%) Mean -280 0 (100%) D. Test Formulation Batch No. 00-27A (lvm, Lev,Abz, SeCo) (1 mL per 4kg 200ug/7.5mg/5.0mg/kg) 351 25.0 6.3 300 0 352 20.3 5.1 100 0 353 25.3 6.3 100 0 354 25.2 6.3 400 0 355 23.1 5.8 200 0 356 26.1 6.5 300 0 357 22.6 5.7 300 0 i 358 25.2 6.3 0 484 29.0 7.3 700 0 485 29.6 7.4 0 0 1 Mean 240 0 (100%) epg eggs per gram TRIAL C0040 SHEEP ROUNDWORM AND TAPEWORM TRIAL Fifty three pasture fed 6-8 month old Romney lambs from the southern North Island, New Zealand that were naturally infected with tapeworms, were orally dosed with three times the standard dose of ivermectin (3 x 0.2 0.6mg/kg liveweight) to remove their naturally acquired roundworm infection while leaving their tapeworm burden. The animals were then housed indoors on slats to prevent natural reinfections with roundworms and each Iamb was orally dosed daily for 5 days with a similar mixture of 5,000 roundworm larvae (total 25,000 larvae) consisting primarily of Haemonchus, Trichostrongylus, Ostertagia and Nematodirus. The larvae originated from four New Zealand sheep farms, three of which had evidence of resistance to one or more drench families. Lambs were injected with 0.5mL of a corticosteroid (opticortenol) two days prior to artificial oral larval infection. This was done to assist establishment of the worm larvae. 25 days after infection the animals were restrictively allocated to groups by bodyweight and also the presence of tapeworm infection, to one 63 of seven treatment groups (Groups Four treatment groups (the untreated control and test products Groups A-D) had 8 animals per group, and three groups (E-G) contained 7 animals per group. The groups with 7 animals per group F, G) were orally dosed with a single standard commercial product. All animals were slaughtered at Day 7 and Day 8 after treatment and total numbers of gastrointestinal roundworms and tapeworms counted. The treatment groups, liveweight and formulation and dose rate data are summarised in Table 29. The worm count data, including tapeworm data is summarised in Table Results Roundworms All products including the three test formulations (LCOO/14, 99/99B, LBOO/09) were highly effective (greater than 95% reduction in worm numbers) against Haemonchus except albendazole which reduced numbers by 93% (based on arithmetic means). The Ostertagia however showed greater resistance with only 54% removal of worm numbers with ivermectin alone and 64% removal by albendazole alone.

Levamisole was still effective at 96% removal but the greatest removal was achieved with the three combination test products.

Against Nematodirus in the small intestine, ivermectin and the three test products were fully effective (100% reduction), levamisole removed 99% of adult Nematodirus and albendazole removed only 59%.

All formulations were fully effective (100%) against Trichostrongylus in the small intestine except albendazole which was 80% effective.

Tapeworms While there appeared to be a slight trend to less Moniezia volume in albendazole treated animals, only the test formulation LBOO/09 with the addition of praziquantel was effective in removing the entire tapeworm (scolex and segments).

64 Conclusion Levamisole alone and the combination test formulations (LBOO/14, 99/99B, LBOO/09) were highly effective against all roundworm species in this trial. Despite not having roundworms with marked resistance to levamisole, the three test formulations removed more worms than any of the single active commercial formulations alone indicating the benefits of combining the actives together in one single formulation.

Additionally only the test formulation with praziquantel was effective in removing the tapeworm Moniezia.

TRIAL C0040 Table 29 Tag Identification, bodyweight, formulation and dose rate Tag I.D. Welght (kg) m> ft niL Tt 4 A. Untreated Control 218 18.3 6189 30.8 A 6163 34.2 6216 32.4 6197 32.6 6151 33.6 6221 34.2 6237 35.2 Mean 31.4 B. Formulation LBOO/14 Ivermectin, Levamisole,'Albendazole (lmL per 4kg, 0.2mg, 7.5mg, 5mg/kg) 6175 28.2 7.1 6236 30.4 7.6 6148 31.5 7.9 6183 32.2 8.1 6168 32.9 8.2 6241 33.5 8.4 6192 31.7 7.9 6156 30.4 7.6 Mean 31.4 C. Formulation 99198B Ivermectin, Levamisole, Albendazole, SeCo (1mL per 4kg, 0.2mg, 7.5mg, 220 19.4 4.9 6174 35.0 8.8 6185 32.0 6226 32.4 8.1 6219 32.6 8.2 6182 33.1 8.3 6240 34.5 8.6 6166 35.5 8.9 Mean 31.8 D. Formulation LB00/09. vermectin, Levamisole, Albendazole, Praziquantel, SeCo (1mL per 4kg, 0.2mg, 7.5mg, 5mg, 3.75mg/kg) 221 25.4 6.4 6154 30.5 7.6 6232 31.0 7.8 6220 32.5 8.1 6152 32.9 8.2 6229 32.2 8.1 6202 33.4 8.4 6149 33.7 8.4 65 Mean 131.5 E. A]lbendazale, Valbazen Batch #51 660, Exp Feb 2001 (1lmL per Skg,'Smglkg)- 6228 27.6 6203 31.0 6.2 6212 32.3 6195 33.0 6.6 6230 35.5 7.1 6190 35.7 7.1 6225 35.8 7.2 Mean 33.0 F. Levamnisole, Nilverm Batch #51930, Exp Nov.2004 (IlmL per 5,3kg, 7.Smglkg)- 6223 29.1 6217 30.1 5.6 6193 32.5 6.1 6207 33.6 6.3 6224 35.0 6.6 6208 35.8 6.8 6157 36.5 6.9 Mean 33.2 6. Ivermectln, Ivomnec Oral 1 Batch #8289, Exp Nov 2002 (1lML per 4kg, 0.2nmgkg) 6171 30.1 6160 30.3 7.6 6239 31.0 7.8 6196 33.9 6170 35.2 8.8 6181 35.6 8.9 6199 36.6 9.2 Mean 33.2 66 Trial C0040 Table Table Total abomasal and small intestinal roundworm and tapeworm count Abomasum rag ls a p Smut Itite~tI'ne t t: VIILK otex& ua n ie (mLfl A. Control P 218 3650 3150 6151 3850 3650 0 2750 3650 1 18 6163 4200 4750 50 2250 3900 4 120 6189 1150 250 0 1550 4200 1 6197 2300 2600 0 100 2550 1 24 6216 2400 2700 50 1250 4300 1 31 6221 5800 3550 0 1600 2600 0 0 6237 1950 850 0 1000 4200 1 Mean 3162 2706 12 1706 3850 1 36 3 Formulation LBOO/14 Ivermectin Eevamisole, Albendazole (lmb"per;4kg 0.2mgh!7.5mg 5mg/kg) t 6148 0 0 0 0 0 5 6156 0 0 0 0 0 1 9 6168 0 0 0 0 0 0 0 6175 0 0 0 0 0 1 6183 0 0 0 0 0 0 0 6192 0 0 0 0 0 1 3 6236 0 0 0 0 0 1 <1 6241 0 50 0 0 0 1 Mean 0 7 0 0 0 1.2 C. Formulation99199B lvermectin,Levamisole,;AIbendazole;SeCo (lmLper4kg,0.,2mg75mg,5mg/kg)W :U A 220 50 0 0 0 0 3 6 6166 0 0 0 0 0 3 <1 6174 0 0 0 0 0 0 0 6182 0 0 0 0 0 0 0 6185 0 0 0 0 0 1 <1 6219 0 0 0 0 0 0 0 6226 0 50 0 0 0 3 31 6240 0 0 0 0 0 2 110 Mean 6 6 0 0 0 2 24 D. Formulation LBOO/09 Ivermectlin evamisole;AlbendazolePraziquantelSCo. (1 mLbper,.4kg,0.2mgi'7:SmgS mg ,t3.76mglkg) 221 0 0 0 0 0 0 0 6149 0 150 0 0 0 0 0 6152 0 0 0 0 0 0 0 6154 0 0 0 0 0 0 0 6202 0 50 0 0 0 0 0 6220 0 0 0 0 0 0 0 6229 0 0 0 0 0 0 0 6232 0 0 0 0 0 0 0 Mean0 25 0 0 0 0 0 Albendazote, Valbazen, Batch #51660; Exp Feb 2001'(1mL per 5kg or.Smg fkg)%Wt45l r," 6190 100 1000 0 1000 1300 1 32 6195 100 1450 0 1200 450 1 2 6203 150 400 0 3250 200 0 0 6212 500 1450 0 2100 900 2 <1 6225 300 650 0 1950 600 2 6228 250 1350 0 1750 350 1 32 6230 150 550 0 2300 1100 2 2 Mean 221 979 0 1936 700 1 14 F. Levamlsole, Nilverm, Batch #51930; Exp Nov2004.(ImUEper 4 5.3kg'or7.5mg/kg A 6157 0 0 0 0 0 7 54 6193 0 200 0 0 0 1 6207 0 450 0 100 0 3 6208 0 50 0 50 0 1 6217 0 0 0 50 0 <1 6223 0 0 0 0 0 5 9 67 6240 0 0 0 0 1 0 MeanO0 100 1 0 29 0 IE3mE42m.

.Ivermectin, Ivomec Batch.i82A9i%,Exp~Nc~i2002:jliLprk~.4m~g 6160 0 1950 0 0 0 1 <1 6170 0 1700 0 0 0 0 0 6181 0 1000 0 0 0 0 0 6196 0 2200 0 0 0 3 el 6199 0 750 0 0 0 1 33 6239 0 950 0 0 0 1 2 39 6171 0 250 0 0 0 6 57 MeanO0 1257 0 -0 0 1.9 26

Claims (20)

1. A storage stable veterinary composition comprising or including at least one active ingredient that is lipophilic in character, (ii) at least one organic liquid carrier which carries at least most of the lipophilic active ingredient(s), thereby defining an organic liquid phase, (iii) levamisole, and (iv) at least water which carries at least most of said levamisole thereby defining an aqueous phase, wherein said aqueous phase has a pH of less than 7, and wherein there is present in said aqueous phase an emulsifying agent or agents, and wherein said phases exist in, or can be shaken or agitated into, the form of an emulsion with any particulate content, if any, at least substantially present in the aqueous phase.

2. A composition of claim 1 wherein the lipophilic active ingredient is chosen from the class of macro cyclic lactones (hereafter

3. A composition as claimed in claim 1 or 2 wherein there is present in said aqueous phase a particulate content.

4. A composition as claimed in any one of the preceding claims wherein said aqueous phase has a pH of less than 6. A composition of claim 4 wherein said aqueous phase has a pH of less than

6. A composition as claimed in claim 5 wherein said aqueous phase has a pH of less than 4.

7. A composition as claimed in any one of the preceding claims wherein said aqueous phase includes a buffering system to buffer the pH. 69

8. A composition as claimed in claim 7 wherein said buffering system is a citric acid/citrate salt system.

9. A composition as claimed in any one of the preceding claims wherein said at least one organic liquid carrier is an oil.

10. A composition as claimed in claim 9 wherein said oil is a mineral or vegetable oil.

11. A composition as claimed in any one of the preceding claims wherein said organic liquid phase includes a co-solvent.

12. A composition as claimed in claim 11 wherein said co-solvent is benzyl alcohol.

13. A composition as claimed in any one of the preceding claims wherein the particulate content of the aqueous phase is either an active agent or an inert substance.

14. A composition as claimed in claim 13 wherein the particulate active agent is a biocide. A composition as claimed in any one of the preceding claims which includes in one or other, or both, of the partitioned phases one or more of the group comprising minerals and vitamins.

16. An anthelmintic composition of about 0.08% ivermectin, about 3% levamisole, and about 2% albendazole where different liquid carrier phases substantially partition the ivermectin from the levamisole, and where the albendazole is particulate and is at least in part in an aqueous phase with the levamisole, such aqueous phase being buffered to a pH appropriate for the levamisole and its stability, and 70 where the ivermectin is substantially in an organic phase.

17. A storage stable pourable veterinary composition comprising or including up to 25% w/v of at least one pesticide (hereafter "first active(s)") soluble in an organic phase, 1 to 60% w/v of an organic phase (hereafter "first liquid phase") in which said first active(s) is (are) at least substantially soluble, 0 5% w/v of a co-solvent for said first active(s), 1 to 1i 5% w/v of an emulsifying agent, 0 to 20% w/v of at least one further pesticidal active (hereafter "second active(s)") not substantially soluble in said first phase, and, a second liquid phase, said composition having at least most of said first active(s) in said organic phase and said organic phase being emulsified in the second liquid phase which includes said second active(s) (when present).

18. A composition of claim 17 wherein said organic phase includes a vegetable and/or mineral oil, (ii) at least one emollient ester, or (iii) both and (ii).

19. A storage stable veterinary composition comprising or including up to 25% w/v of at least one pesticide (hereafter "first active(s)") chosen from the class of at least partly oil or emollient ester soluble actives, 1 to 60% w/v of at least one water immiscible organic phase in which said first active(s) is (are) at least substantially soluble, 0 5% w/v of a co-solvent for said first active(s), 1 to 15% w/v of an emulsifying agent, -71- up to 20% w/v of at least one further pesticidal active (hereafter "second active(s)") not substantially soluble in said organic phase which is dissolved in water and/or (ii) suspended in water, and, said water, said composition having an organic phase with at least most of said first active(s), said organic phase being emulsified in an aqueous phase of said water and said second active(s). A storage stable veterinary composition as claimed in claim 19 wherein the composition is a concentrate for aqueous dilution.

21. A storage stable pesticidal veterinary composition (whether as a concentrate for aqueous dilution or otherwise) comprising or including at least one active ingredient chosen from the class of macro cyclic lactones (hereafter at least one active ingredient chosen from the tetramisole/levamisole class, at least one organic liquid carrier, and water, and, optionally, an emulsifying agent or agents, wherein said ML active ingredient(s) is(are) at least primarily in the organic liquid carrier(s) in solution (hereafter referred to as "the organic phase"), and wherein said tetramisole/levamisole class active ingredient(s) is(are) at least primarily in solution in the water (hereafter referred to as "the aqueous phase"), and wherein said organic phase and said aqueous phase exist in, or can be shaken or agitated into, the form of an emulsion.

22. A composition of claim 21 wherein said at least one organic liquid carrier is at least one oil or (ii) at least one oil and at least one organic co-solvent.

72- 23. A storage stable pesticidal veterinary composition comprising or including at least one active ingredient chosen from the class of macro cyclic lactones (hereafter (ii) at least one organic liquid carrier which carries at least most of said ML active ingredient(s), thereby defining an organic liquid phase, (iii) levamisole, and (iv) at least water which carries at least most of said levamisole thereby defining an aqueous phase, wherein said aqueous phase has and/or is buffered to a pH of less than 7, and wherein there is present in said aqueous phase either or both an emulsifying agent or agents, and a particulate content, and wherein said phases exist in, or can be shaken or agitated into, the form of an emulsion with said particulate content, if any, at least substantially present in the aqueous phase. 24. A storage stable veterinary anthelmintic oil in water emulsion carrying at least one macro cyclic lactone (ML) in the oil phase and particles of levamisole and an emulsifying agent for the levamisole in the aqueous phase. 25. A method of formulating a storage stable veterinary anthelmintic composition having at least one anthelmintic (hereafter "first active(s)"), a liquid or liquids to define a first phase in which said first active(s) is (are) at least substantially soluble, (optionally) an emulsifying agent, levamisole (hereafter "second active(s)") not substantially soluble in said first phase -73- (optionally) anti-flocculant(s), and, a liquid or liquids to define a second phase, said method comprising or including the steps of providing a mix of said first active ingredient and at least the first phase liquid(s), providing a mix of said second active ingredient and at least the second phase liquid(s), and (II) by mixing at least the mixes of and forming an emulsion with at least most of said first active in the first phase and at least most of the second active in the second phase. 26. A method of formulating an anthelmintic composition having at least one anthelmintic (hereafter "first active(s)") chosen from the class of (at least partly) oil soluble anthelmintic actives, an oil or oils in which said first active(s) is (are) at least substantially soluble, optionally a co-solvent for said first active(s), an emulsifying agent, levamisole (hereafter "second active(s)") not substantially soluble in said oil(s), optional anti-flocculant(s), and, water, said method comprising or including the steps of providing a mix of said first active ingredient, the oil(s), the optional co-solvent(s) and the emulsifying agent(s), 74 providing a mix of said second active ingredient the water, and the optional anti-flocculant(s), and (II) by mixing at least the mixes of and forming an emulsion with at least most of said first active in the oil(s) and at least most of the second active in the aqueous phase. 27. An anthelmintic composition made by a method of claim 25 OR 26. 28. A method of treating mammals for pests which involves (whether with dilution or not) administering or having self administered to such mammals effective amounts of active(s) of compositions of any one of claims 1 to 24 and 27. 29. The use of an anthelmintic composition of any of the kinds defined in any one of claims 1 to 24 and 27. A storage stable partitioned biocidal veterinary composition comprising in an organic phase a first biocide, and in an aqueous phase at acid pH a second biocide, said first biocide being unstable chemically at said acid pH of the aqueous phase. 31. A partitioned biocidal composition as claimed in claim 30 having particles suspended in at least the aqueous phase. 32. A partitioned biocidal composition as claimed in claim 31 wherein said particles are themselves biocidal. 33. A partitioned biocidal composition as claimed in claim 32 wherein said particles are of a benzimidazole anthelmintic. 34. A partitioned biocidal composition of claim 31, 32 or 33 wherein said particles are substantially all less than A partitioned veterinary biocidal composition of any one of claims 30 to 34. 36. A partitioned composition of any one of claims 30 to 34 which is also a composition of any one of claims 1 to 24 and 27. 37. A storage stable veterinary composition of at least one macrocyclic lactone levamisole, and at least one benizimidazole 75 wherein the weight relativity of the ML:levamisole:BZ is substantially 0.04:1.5:1, and wherein different liquid carrier phases substantially partition the ivermectin from the levamisole, and wherein the albendazole is particulate and is at least in part in an aqueous phase with the levamisole, such aqueous phase being buffered to a pH appropriate for the levamisole and its stability, and wherein the ivermectin is substantially in an organic phase.